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Abstract
Studies show that Menin, a tumour suppressor encoded by the multiple endocrine
neoplasia type 1 (Men1) gene, is required during murine pancreatic development. In
humans, mutation results in the MEN1 tumourigenic syndrome; however, knowledge of
menin in human pancreatic development is limited. This study examined the expression
pattern and functional role of menin during human fetal islet development.
Immunostaining revealed the presence of nuclear menin within pancreatic cells from the
1st through 2nd trimester co-localizing with various developmental factors. Knockdown
of MEN1 in human fetal islet-epithelial cells significantly increased apoptosis, reduced
proliferation, and decreased SOX9, NKX2.2, and NKX6.1 mRNA levels (transcription
factors required in maintenance of the progenitor pool and endocrine differentiation).
Overexpression of MEN1 confirmed these results suggesting that menin promotes cell
survival and proliferation, maintains the islet progenitor pool, and regulates islet
differentiation in the human fetal pancreas: a different function compared to its antitumourigenic role during adulthood.
Keywords: MEN1, Menin, human fetal pancreas, islet-epithelial cell clusters,
endocrine differentiation, MEN1 overexpression, MEN1 knockdown
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Chapter 1

Introduction

2
Chapter 1 – Introduction
1.1

Significance of the Study

The increasing prevalence of diabetes mellitus worldwide continues to be a growing
concern. In the past decade, the prevalence has more than doubled with projections to
increase another 54% from 2010 to 2030 (Chen et al., 2012). This will amount to 7.7%
of the total adult population worldwide (ages 20-79 years old), illustrating the need for
continued development of cost-effective and efficient treatments, as well as a potential
cure for diabetes.
Diabetes mellitus is a chronic metabolic disease characterized by an abnormally high
blood glucose level (hyperglycemia), where the body in unable to use or uptake glucose
adequately. Insulin, a hormone produced and secreted by pancreatic beta-cells (found in
islets of Langerhans), is involved in lowering blood glucose levels. The two main types
of diabetes are classically described as either a deficiency in insulin production due to an
auto-immune destruction of islet beta-cells (Type 1) or the inability of target cells to
respond to insulin (called insulin resistance, Type 2) (Kim and Hebrok, 2001; Sander and
German, 1997). However, type 2 has a complex pathophysiology encompassing insulin
resistance, loss of normal beta-cell function and a reduction in beta-cell mass (all of
which vary to certain degrees between patients) resulting in a relative insulin deficiency
similar to Type 1 (Donath and Halban, 2004). Insulin-replacement therapy is used to
treat type 1 patients. Some type 2 patients will also require insulin-replacement therapies
if target glucose control cannot be maintained with oral hypoglycemic medications (Kim
and Hebrok, 2001; Riethof et al., 2012; Tan et al., 2011). Over the past few decades, the
leading edge in insulin-replacement therapy research has focused on beta-cell
replacement therapy through the transplantation of islets and overcoming the numerous
obstacles involved in this procedure. Some drawbacks have included the lack of donor
islet material, the need for life-long immunosuppression, and the declining survival and
function of the grafted beta-cells (Senior et al., 2012).
My specific research focus contributes to the broader goal of enhancing the production
of more viable and functionally efficient islet beta-cells from existing pancreatic cells,
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pancreatic progenitor cells, or stem cells.

Current research in the production of

functional insulin-secreting cells has noted that engineered cells showed insufficient
functionally, low differentiation efficiency,

and numerous side effects post

transplantation (Liu et al., 2013; Seymour and Sander, 2011). By understanding fetal
beta-cell development, its intricate process, and the network of factors and pathways
involved, this will give insight into furthering the production and overcoming the
obstacles of engineered beta-cells (Seymour and Sander, 2011; Wells, 2003).

My

research aims to further the understanding of transcription factor expression patterns,
functions, and the network involved in islet differentiation during human fetal pancreatic
development. Specifically, this project looks at the involvement of the transcription
factor menin in the developing human fetal pancreas and its interactions. Menin is
encoded by the MEN1 gene, named for the disease which its mutation causes, Multiple
Endocrine Neoplasia type 1, in adult tissues (Bertolino et al., 2003a; Stewart et al.,
1998). Studies in the developing rodent pancreas have revealed a requirement for the
protein menin in progenitor and endocrine differentiation; an altered function compared
to its anti-tumourigenic role within adult tissues (Fontaniere et al., 2008). We have
recently characterized the transcriptional profiles of islet progenitor cells during human
fetal pancreatic development (Lyttle et al., 2008) and our microarray investigation of 821 week human fetal pancreata revealed that MEN1 is highly expressed relative to adult
pancreatic islets.

Genes encoding proteins involved in Menin-regulated signaling

pathways in the developing mouse pancreas (e.g. Wnt/β-catenin, TGF-) are highly
upregulated in parallel cells, suggesting that Menin may play a role in regulating
endocrine cell differentiation. This study will examine whether this altered function
between fetal and adult tissues is recapitulated in the developing human fetal pancreas as
was seen in rodents and provide us with a better sense of how human islet cells develop.

4
1.2

Pancreatic Development

1.2.1

The Human Pancreas

The human pancreas is a vital complex organ functioning to produce hormones and
enzymes regulating nutrient homeostasis. It can be found in the retroperitoneal region
and is comprised of four distinct regions: the head, neck, body and tail. The head is
located on the right side of the body adjacent to the duodenum (the first section of the
small intestine) where the main pancreatic duct connects to the common bile duct and the
narrow pancreatic tail extends to the left side of the body to lie adjacent to the spleen
(Slack, 1995). In humans, this organ can weigh between 70 to 150 grams and measure
15-25 cm in length. The pancreas is composed of two distinct glandular tissues: the
exocrine compartment which is comprised of ducts and acini makes up over 90% of the
pancreas

and

produces

digestive

enzymes,

and

the

endocrine

compartment

(approximately 1-2%) which is organized into structures known as islets of Langerhans
(Cleaver, 2010; Slack, 1995).
Islets are embedded within the exocrine tissue and are responsible for producing and
secreting hormones into the blood stream for regulation of glucose homeostasis (Slack,
1995).

The islets of Langerhans are composed of 5 principle cell types including

glucagon secreting alpha (α)-cells, beta (β)-cells secreting insulin, delta (δ)-cells secreting
somatostatin, epsilon (ε)-cells secreting ghrelin, and pancreatic polypeptide (PP)containing PP-cells. The various hormones function such that insulin reduces blood
glucose, glucagon increases blood glucose, somatostatin regulates alpha- and beta-cell
secretion, PP suppresses exocrine enzyme secretion and appetite, and ghrelin acts to
inhibit insulin secretion and increase appetite (Lin and Chance, 1974; Pusztai et al., 2008;
Rovasio, 2010; Ueno et al., 1999). Unlike murine islets which are structured with a betacell core, human islets have a distinct morphology where beta-cells are intermingled with
various endocrine cells throughout the islet. This yields fewer beta-cells in the human
pancreas and more alpha-cells such that there are approximately 60% beta-cells, 30%
alpha-cells, 10% delta-cells, <5% PP-cells, and fewer still epsilon-cells, however
proportions vary throughout the organ. The human islet also differs both morphologically
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and physiologically from the murine islet in that all of the endocrine cell types (in no
particular order or layer) are closely associated with the islet’s microcirculation (Cabrera
et al., 2006). Apart from the production of hormones, endocrine cells can also express
gene products characteristic of neuroendocrine cells, and can be found throughout the
gastrointestinal tract (Slack, 1995).

1.2.2

Morphological Development of the Human Pancreas

The pancreas initially develops with the outcropping of a dorsal and ventral bud at the
mid-foregut boundary on either side of the primitive gut tube, an endoderm-derived
structure. Budding is induced by various extracellular environmental signals emanating
from the adjacent notochord, dorsal aorta, and lateral plate mesoderm which lead to the
expression of various pancreatic genes (Jorgensen et al., 2007; Piper et al., 2004; Wells,
2003). In humans, pancreatic bud development is initiated at two to three weeks of fetal
age whereby the dorsal bud first emerges, sprouting into the surrounding mesenchyme,
followed by the ventral bud a few days later (Jeon et al., 2009; Lyttle et al., 2008). A
human pancreatic developmental timeline is shown in Figure 1.1.

The partially-

differentiated epithelium of the two buds begins to form a ductal tree through branching
morphogenesis, resulting in two predominantly ductal preliminary pancreata (Habener et
al., 2005; Rutter et al., 1968). Between weeks 5 and 7 the gut tube (duodenal loop)
rotates, translocating the ventral rudiment into contact with the dorsal bud where they
fuse and their ductal systems become interconnected, forming the definitive pancreas
(Polak et al., 2000). The ventral bud forms the posterior portion of the pancreatic head
(the uncinate process) while the dorsal bud gives rise to the major portion of the head as
well as the body and tail of the future pancreas (Slack, 1995).
Hormone-expressing endocrine cells can be detected by around 8 weeks of fetal age
(wks), expressing insulin and often co-expressing glucagon or somatostatin (Jeon et al.,
2009; Polak et al., 2000). At about 9 wks, PP-expressing cells appear and the percentage
of hormone co-expression drops dramatically (Polak et al., 2000). These initial endocrine
cells appear mainly as single cells, dispersed throughout the central epithelial ductal
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Figure 1.1.

Human Pancreatic Developmental Timeline.

An approximate gestational timeline outlining the major morphological changes
occurring during human pancreatic development. The fetal age in weeks (wks) is shown
where the first and second trimesters of pregnancy are key to pancreatic development.
The first trimester of pregnancy occurs until the end of the 11th wk of fetal age, the
second trimester is designated from 12 to 24 wks, and the third trimester is the gestational
period from the 25th week up until birth (approximately 40 wks). Figure by Dr. Rennian
Wang.

7

Figure 1.1.

8
structure, either within the ducts themselves or in small groups in contact with the duct.
Thus, endocrine progenitors are thought to arise from pancreatic progenitors or stem cells
within the ductal epithelium and not through endocrine proliferation (Bouwens et al.,
1997; Polak et al., 2000). Early endocrine progenitors may divide into distinct lineages
but may not necessarily generate mature endocrine cells (Fontaniere et al., 2008; Habener
et al., 2005; Herrera, 2000). For exocrine cell differentiation, mesenchymal signals are
required; without these signals, cells will resort to an endocrine cell fate (Habener et al.,
2005). As development proceeds, endocrine cell density increases within the center of
the pancreas and expands towards the periphery of the pancreas (Jeon et al., 2009; Polak
et al., 2000). During the period of 10 to 12 weeks of fetal age, proliferation of branched
tubules continues into exocrine acini, islets, and ducts with limited differentiation (Lyttle
et al., 2008).
From 12 to 16 wks, there is a dramatic increase in insulin and glucagon expression
suggesting that this period is especially important for endocrine cell development and
hormonal expression (Lyttle et al., 2008). Differentiation is brought on by a drastic
increase in pancreas-specific protein synthesis and a decrease in cellular proliferation
(Jorgensen et al., 2007; Rutter et al., 1968). Analysis of 14 to 16 wk pancreata shows the
appearance of vascularized parenchymatous lobules containing small islet clusters
expressing all four hormones (insulin, glucagon, somatostatin, and PP) (Gupta V, 2002;
Piper et al., 2004). Mature beta-cell markers such as prohormone convertase 1/3 (PC1/3)
and islet amyloid polypeptide (IAPP) are first detected centrally in islets during this time
period denoting that these beta-cells may be able to process and secrete insulin (Piper et
al., 2004).

The exocrine cell populations, embedded in dense mesenchymal tissue,

differentiate and aggregate together at the lateral and terminal ends of the primitive ducts,
forming acinar cells. Within acinar cells at this stage, zymogen granules, exocrine
enzyme activity, and acinar cell markers are detectable (Bouwens et al., 1997; Rovasio,
2010). All epithelial cells at this point express CK19 (Cytokeratin 19: a ductal and
epithelial cell marker), which includes most endocrine cells since most endocrine cells
are still in close contact or within the ductal epithelium at 16 wks of fetal age (Bouwens
et al., 1997).
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From 18-24 wks, islets show a decrease in CK19 intensity staining (immunofluorescence
staining), where single cells and small aggregates still stain strongly for CK19 (Bouwens
et al., 1997). This denotes a transitional period as the endocrine cells begin to lose their
ductal cell marker as they migrate through the basal membrane and into the surrounding
mesenchyme (Bouwens et al., 1997; Kim and Hebrok, 2001). By the end of the second
trimester of pregnancy (24 wks of fetal age), the pancreas is almost fully developed
showing adult-like islets characterized by larger, well-encapsulated, closely-packed cells
with all endocrine granules well established in the cytoplasm. The pancreas has an
extensive vascular network, mesenchymal tissue is reduced due to acinar proliferation,
and the parenchyma overall is well organized into lobes and lobules throughout the
pancreas (Gupta V, 2002; Lyttle et al., 2008).
During the 3rd trimester until birth (25 to approximately 40 wks) the pancreas continues
to mature, where connective tissue condenses and compacts around the ducts, islets
increase in number and are widely distributed (lose their ductal association, CK19-), with
some islets close to acini while few lie within interlobular connective tissue. At birth a
well-defined architecture characteristic of a fully-formed and functional pancreas is
observed with dense hormone granules present in endocrine cells with well formed acini
and ductal systems (Bouwens et al., 1997; Gupta V, 2002).
Throughout development and into adulthood, beta-cells and alpha-cells show very low
proliferation activity which may demonstrate the importance of islet neogensis from
hormone-negative cells or pancreatic progenitor

cells during these time periods

(Bouwens et al., 1997). It has been suggested that these pancreatic progenitors, from
development into adulthood, reside around the ductal epithelium due to the high
proliferation capacity of CK19+ cells, as well as the subsequent co-localization and loss
of the CK19 marker in endocrine cells.

The differentiation of hormone-negative

pancreatic cells and pancreatic stem cells are both possible opportunities to further
pancreatic cell-based therapeutics (Bouwens et al., 1997; Wells, 2003).
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1.2.3

Transcriptional Profiling of Pancreatic Development

Pancreatic development and beta-cell differentiation is an intricate process which consists
of multiple transcription factors precisely regulated temporally and spatially (Lyttle et al.,
2008). Studies using mouse models, as well as cultured or differentiated cell lines, and
primary cell cultures have provided the necessary tools to study and elucidate the
function of various transcription factors and signalling molecules involved in
development. Based on the information and function from these studies, I will highlight
the main transcription factors analyzed in my study, focusing on pancreatic and endocrine
progenitors as well as the network involved in endocrine lineage determination (Figure
1.2). These critical transcription factors include PDX1, NGN3, HES1, ISL1, SOX9,
NKX2.2, and NKX6.1.

PDX1 (Pancreatic Duodenal Homeobox 1)
The PDX1 gene, which has various alternative names including IPF-1, IDX-1, and STF-1,
is a member of the ParaHox group of homeodomain transcription factors (Habener et al.,
2005; Kim and Hebrok, 2001). Studies have shown that PDX1 is required for pancreas
development in both rodents and humans, where it serves to play a role in endoderm
specification of the two pancreatic buds as well as pancreatic progenitor differentiation.
As development proceeds, PDX1 also plays a role in beta-cell maturation, maintenance,
and function (Kim and Hebrok, 2001; Lyttle et al., 2008). It is first detected around 3.5
wks or embryonic day 8.5 in mice (e8.5) in a narrow band of fore-gut endoderm, soon
after it is seen in both dorsal and ventral buds and expressed throughout the ductal tree.
From 6-11 wks of fetal age, PDX1 is detected in all types of pancreatic epithelial cells
which are destined to form islets, ductal structures, and acini (Lyttle et al., 2008; Piper et
al., 2004). As development proceeds and islets begin to form into hormone-producing
cells, co-localization becomes restricted to the endocrine compartment such that by e18.5
(~16 wks) PDX1 is mostly restricted to mature beta-cells with lower levels in CK19+
ductal cells (Habener et al., 2005; Lyttle et al., 2008; Piper et al., 2004).

During

development PDX1 is expressed in a few glucagon-producing cells early on in develop-
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Figure 1.2.

Schematic Diagram of Endocrine Lineage Determination

This figure outlines the lineage of endocrine determination from progenitors to fully
differentiated cells and the transcription factors involved. Diagram is based on studies
outlined in the main text and describes only transcription factors that are addressed in this
study. Even though many of these transcription factors play a role at different times
throughout pancreatic development, one time point is depicted here, indicating the
predominant timing of its function. The colours shown are representative of the different
cell types during lineage determination. Adapted from Habener, Kemp, and Thomas,
2005 as well as Cleaver and MacDonald, 2010.
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Figure 1.2.
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ment, where its expression is weaker than in both progenitor and beta-cells; however no
PDX1-glucagon co-localization is seen later in development and into adulthood (Habener
et al., 2005; Jeon et al., 2009; Lyttle et al., 2008).
Expression of PDX1 in the adult pancreas is undetectable in the exocrine compartment
with expression in sub-populations of somatostatin and PP-cells (Habener et al., 2005).
Although its expression remains in ductal cells, PDX1 is more strongly expressed in islets
as studies have shown that it regulates the expression of islet-specific genes. In beta-cells
PDX1 regulates glucose-induced insulin gene expression (Habener et al., 2005; Piper et
al., 2004). Pdx1 null mice are viable but die soon after birth as a result of pancreatic
agenesis where preliminary buds form but then regress during development. Normal
pancreatic mesenchyme is detected but the pancreatic epithelium is unable to respond to
these mesenchymal signals which are required for differentiation of all pancreatic cell
types.

This suggests that Pdx1 is required for the endodermal response to signals

emanating from the mesenchyme (Habener et al., 2005; Kim and Hebrok, 2001).
Similarly, a child born without a pancreas could be homozygous for an inactivating
mutation of PDX1 (Habener et al., 2005). Due to the involvement of PDX1 in insulin
production, a heterozygous mutation results in islet defects ranging from impaired
glucose regulation to insulin-dependent diabetes such as MODY4 (maturity onset
diabetes of the young type 4) (Habener et al., 2005; Wells, 2003). In these cases,
diabetes is the result of a PDX1 haploinsufficiency or a dominant negative inhibition of
the normal allele (Habener et al., 2005). These studies have demonstrated the important
role of PDX1 at different developmental stages and its requirement throughout pancreatic
development and into adulthood for both the murine and human pancreas (Habener et al.,
2005; Kim and Hebrok, 2001).

SOX9 (SRY (Sex Determining Region Y)-Box 9)
SOX9 is a member of the SRY homeobox family of transcription factors and has been
implicated in the development of various organs. Humans and mice with a SOX9
haploinsufficiency develop Campomelic dysplasia and die either during development or
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at term (rare). Analysis of their pancreata illustrates reduced islet size, loosely packed
islets, and a reduction of mature insulin cell markers, suggesting a role for SOX9 in
endocrine development (Piper et al., 2002; Seymour et al., 2008). Studies have shown
that SOX9 is initially highly expressed in the pancreatic primordium at around 3.5 wks of
fetal age, highly expressed as the two buds fuse, at 10-12 wks its expression declines, and
is even further reduced at 19-21 wks. At 19-21 wks SOX9 expression is mainly restricted
to a subpopulation within ductal cells and is excluded from lineage-committed endocrine
progenitors. This expression pattern suggests that SOX9 must be down-regulated for
endocrine differentiation to proceed and demonstrates a lack of expression in mature
endocrine cells (McDonald et al., 2012; Piper et al., 2002; Seymour et al., 2007). SOX9expressing cells reside in a pool of proliferating progenitor cells, co-localizing with
various endocrine-specific factors such as NGN3, NKX2.2, NKX6.1, and ISL1
(McDonald et al., 2012; Seymour et al., 2007). SOX9 has been shown to bind the NGN3
promoter and studies have revealed that its expression is SOX9-dependent, suggesting
that SOX9 is involved in kick-starting endocrine differentiation (McDonald et al., 2012;
Seymour et al., 2008). Sox9 null mice present with agenesis of the pancreas, where
embryos at e11.5 (before endocrine differentiation) show an increased ratio of
Glucagon+/Pdx1+ cells, increased Isl1+ cells, reduced Hes1+ exocrine cells, reduced
proliferation, and increased apoptosis, all of which suggest a crucial role of SOX9 in
maintaining the pancreatic progenitor pool (Seymour et al., 2007). Human knockdown
studies using SOX9 siRNA in human fetal islet-epithelial cell clusters also show reduced
proliferation, reduced endocrine markers, and reduced insulin expression with an increase
in alpha-cells demonstrating a necessary role in pancreatic development (McDonald et
al., 2012). Overall, these studies outline the requirement of SOX9 in maintenance of the
progenitor pool as well as endocrine differentiation for both the murine and human
pancreas.
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NGN3 (Neurogenin 3)
The transcription factor NGN3, is a member of the basic helix-loop-helix (bHLH) family
and is essential for the establishment of endocrine cell differentiation. It is first observed
co-localizing with PDX1, insulin, and glucagon in early development (8-10 wks) with
significant decreases in NGN3 co-localization as development proceeds (Lyttle et al.,
2008). In the rodent pancreas, Ngn3 expression begins at e9-9.5, peaks at e15.5 during
the major wave of endocrine neogensis, and is greatly reduced at birth with little or no
expression in the adult pancreas (Gradwohl et al., 2000). In rodents, Ngn3 can induce
endocrine gene expression (i.e. Insulin), but unlike in humans, it is not observed colocalizing with Insulin or Glucagon (Gradwohl et al., 2000; Lyttle et al., 2008). In the
fully developed or adult human pancreas, NGN3 expression in alpha- and beta-cells is
minimal but NGN3 can be found around the periphery of islet cell clusters; this suggests
the presence of endocrine precursor populations surrounding the adult islet (Lyttle et al.,
2008).
The Notch signalling pathway has been shown to be involved in endocrine and exocrine
differentiation in a lateral inhibition model similar to neurogenesis, whereby a cell
destined to become endocrine (NGN3+) inhibits adjacent cells driving them towards
exocrine cell fates. The expression of NGN3 leads to the expression of notch ligands
which activate notch receptors on adjacent cells. Upon notch activation the transcription
factor, HES1 (see below for description), becomes expressed in the adjacent cell which
acts to repress NGN3 expression and other target genes to repress the endocrine cell
phenotype and promote the exocrine cell fate. Thus, HES1 is not expressed in the
endocrine compartment of the pancreas (Habener et al., 2005). Additionally, the timing
of NGN3 is key in pancreatic development. Mice with Ngn3 overexpression exhibit
small, poorly branched buds (at e12) with accelerated endocrine differentiation and
reduction in pancreatic progenitors with specific reduction in the ability to form the
exocrine pancreas (Habener et al., 2005; Kim and Hebrok, 2001). The ectopic induction
of PDX1 and NGN3 expression was able to induce pancreatic endocrine gene expression
and insulin production in various cells including human embryonic stem cells, pancreatic
ductal cells, hepatocytes, and bone-marrow derived mesenchymal stem cells (BM-MSCs)
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(Limbert et al., 2011). Reduced or null Ngn3 expression results in distorted hypoplastic
islets with impaired glucose homeostasis where endocrine cells are few or absent and
accumulated secretory granules are observed, outlining a role for Ngn3 in normal
exocrine differentiation as well (Kim and Hebrok, 2001). These studies outline the
requirement of NGN3 expression for the establishment of all endocrine cell lineages, thus
NGN3 can be used as a marker of islet precursor cells (Habener et al., 2005).

ISL1 (Islet-1)
ISL1 is a LIM homeodomain protein downstream of NGN3. In humans, its expression is
progressively increased from 8-21 wks co-localizing with endocrine cell markers (PDX1,
insulin, glucagon, somatostatin, and PP but not amylase+ (exocrine cells)). The same colocalization is observed in adulthood suggesting that ISL1 is required for endocrine
differentiation and their functional maintenance (Lyttle et al., 2008). Inactivation of Isl1
has been shown to cause developmental arrest and death at around e9.5, whereby the
dorsal mesenchyme has failed to develop resulting in complete agenesis of the dorsal
aorta and the dorsal pancreatic bud with the absence of all endocrine cells (Habener et al.,
2005; Jensen, 2004). These studies suggest that ISL1 is required for formation of the
dorsal (not ventral) pancreatic mesenchyme, dorsal budding, endocrine differentiation,
and maintenance of their function through adulthood (Jensen, 2004; Jeon et al., 2009).

NKX2.2 (NK2 Homeobox 2/NK2 Related Transcription Factor Related, Locus 2)
NKX2.2 is a member of the NK2 family of homeobox protein transcription factors and is
also known as NKX2B (Habener et al., 2005; Sussel et al., 1998).

In the murine

pancreas, Nkx2.2 is found in the early buds (e9.5) where it is expressed by all pancreatic
cells until endocrine and exocrine differentiation becomes apparent and then becomes
restricted to endocrine cells. In humans, NKX2.2 is up-regulated from 8-21 wks in all
endocrine cell types with highest expression in alpha- and beta-cells at 14-16 wks
(Habener et al., 2005; Lyttle et al., 2008; Sussel et al., 1998). Knockout Nkx2.2 mice are
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viable but present with severe hyperglycemia a few days after birth and die soon after.
Analysis of their pancreas revealed an altered endocrine lineage program, where all betacells, few alpha-cells, and a subset of PP-cells failed to differentiate and were replaced by
an increase in ghrelin-producing endocrine cells (Prado et al., 2004; Sussel et al., 1998;
Wells, 2003). Within endocrine progenitors Nkx2.2 and Ngn3 are co-expressed, where in
the absence of Ngn3, Nkx2.2 expression is absent, and within the Nkx2.2 null pancreata,
Ngn3 expression is reduced (consistent Ngn3+ cell population).

This suggests that

Nkx2.2 and Ngn3 could regulate each other in a feedback loop (Anderson et al., 2009).
The exocrine compartment is not affected by Nkx2.2 loss of function and heterozygous
mutations of Nkx2.2 show no significant changes when compared to their wild-type litter
mates (Sussel et al., 1998). Nkx2.2 mutations have shown that this gene is responsible for
repressing the beta- to alpha-cell transition in both developmental stages and postnatally
(Papizan et al., 2011). NKX2.2 has also been shown in the adult islet to be responsible
for mature beta-cell function (Doyle and Sussel, 2007; Lyttle et al., 2008). All of these
previous studies outline a crucial role for NKX2.2 both during pancreatic development
and in the adult pancreas.

NKX6.1 (NK6 homeobox 1/NK6 related transcription factor related locus 1)
NKX6.1 is a member of the NK6 family of homeobox protein transcription factors. Its
expression occurs at increasing levels in beta-cells only through development from 7-21
wks, and it is not expressed in any other pancreatic cell type in humans (Jeon et al., 2009;
Lyttle et al., 2008; Rudnick et al., 1994). Conversely, in murine models, Nkx6.1 is also
shown to be initially expressed at low levels in the pancreatic buds and in all epithelial
cells. Upon the appearance of endocrine cells, its expression is reduced further in nonbeta-cells and dramatically increased in beta-cells, such that Nkx6.1 is only detectable in
beta-cells at the major wave of endocrine differentiation (Oster et al., 1998; Sander et al.,
2000). In Nkx6.1 knockout murine models, Nkx6.1 suppresses Glucagon expression and
enhances Insulin secretion showing that Nkx6.1 is involved in alpha- and beta-cell
differentiation (Lyttle et al., 2008). In these knockouts, mice at birth have a reduction of
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only beta-cells with a normal assortment of other endocrine cell types, normal bud
formation, and no change in the exocrine compartment (Habener et al., 2005; Sander et
al., 2000). Analysis of the early null pancreas show no alteration in beta-cell numbers
until after the major wave of differentiation (e13) suggesting that Nkx6.1 may be
exclusively required for this second wave (the major wave) of beta-cell differentiation,
downstream of Nkx2.2 (Sander et al., 2000). It has also been suggested that Nkx6.1 may
work in combination with Nkx2.2 to repress the beta- to alpha-cell transition during
development and into adulthood (Papizan et al., 2011).

These various studies

demonstrate the requirement of NKX6.1 during beta-cell differentiation as well as during
adulthood where it maintains β-cell function.

HES1 (Hairy and Enhancer of Split 1)
HES1, also known as HRY (Hairy), is expressed in non-endocrine cells and denotes cells
destined to become the exocrine compartment of the pancreas. HES1 is dominantly
expressed from 7-21 wks of fetal age in pancreatic buds and pancreatic epithelial
precursors with levels gradually decreasing (Jeon et al., 2009). As aforementioned,
activation of Notch receptors, by NGN3-encoded ligands, signals the expression of
HES1. This expression encodes a bHLH repressor capable of repressing the NGN3 gene
promoter, thereby suppressing the downstream endocrine signalling program.

Thus,

HES1 is not expressed in endocrine cells (Habener et al., 2005; Jensen, 2004; Kim and
Hebrok, 2001). Mice homozygous for Hes1 disruption show characteristics similar to that
of Ngn3 overexpression mice with an overabundance of endocrine cells, rapid declines in
pancreatic progenitor cells, acinar apoptosis, and hypoplasia (Habener et al., 2005; Kim
and Hebrok, 2001). Overall, these experiments suggest that HES1 is required for normal
endocrine and exocrine differentiation from pancreatic precursor cells.

19
1.3

The Transcription Factor Menin

1.3.1

Menin Expression and the MEN1 Disease

Current research in murine species has implicated the transcription factor Menin, encoded
by the MEN1 gene, as a necessity throughout pancreatic development and has provided
insight into its possible function (Bertolino et al., 2003a; Stewart et al., 1998). The
human MEN1 gene was initially isolated, characterized, and named for the disease that its
mutation causes, Multiple Endocrine Neoplasia type 1 (MEN1) (Larsson et al., 1988).
The menin protein is found to be ubiquitously expressed throughout the body in tissues
from the endocrine system to nervous, digestive, reproductive, and immune systems in
various species including humans, rodents, and zebrafish (Chandrasekharappa et al.,
1997; Khodaei et al., 1999; Maruyama et al., 1999).
In endocrine cells, a germline mutation and subsequent loss of heterozygosity of the
MEN1 allele results in lack of menin expression or function, tumourigenesis, and multiple
endocrine neoplasia in both mice and humans (Larsson et al., 1988; Yamaguchi et al.,
1980). A patient is diagnosed with this autosomal dominant disease if they have two or
more tumours that originate from parathyroid, pituitary, or gastro-entero-pancreatic cells
or if they present with three of the five main endocrine tumours described by Dreijerink
et al in 2006 (Brandi et al., 2001; Larsson et al., 1988; Yamaguchi et al., 1980). A carrier
with one or more of the 500+ possible germ line mutations can expect 94-100%
penetrance by fifty years of age and more specifically, pancreatic islet tumours have been
found in 30-80% of patients (Balogh et al., 2006; Brandi et al., 2001; Chandrasekharappa
et al., 1997; Dreijerink et al., 2006a; Fontaniere et al., 2008; Lemos and Thakker, 2008).
Islet tumours can be a major cause of death in humans due to malignancy and the major
complications associated with this type of tumour (Fontaniere et al., 2008). Types of
complications can depend on their location in the pancreas, which cells are affected, and
what hormones are being overexpressed.
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1.3.2

MEN1 Characterization & Menin Functionality

From analyzing the MEN1 gene or the menin protein, studies have found that it has no
homology to any known proteins and has few identifiable functional motifs (Biondi et al.,
2004; Chandrasekharappa et al., 1997). The MEN1 gene, found on 11q13 in humans, has
been shown to include two independent nuclear localization motifs at the C-terminus, 2
nuclear export signals (NES) found in two leucine zippers, a proline rich C-terminal, and
5 GTP consensus sequences on the N-terminal (Cao et al., 2009; Chandrasekharappa et
al., 1997; Guru et al., 1998; Larsson et al., 1988; Yaguchi et al., 2002). Being mainly
nuclear, menin may also directly bind double stranded DNA non-specifically through its
nuclear localization sequences (NLS) thereby functioning as a tumour suppressor (Guru
et al., 1998; La et al., 2004).
To characterize the functionality of menin as a tumour suppressor, researchers have
focused on identifying molecules that menin may interact with. A detailed summary of
Menin interactions, as mentioned below, is shown in Figure 1.3. Studies suggest that
menin regulates proliferation and cell death through DNA repair mechanisms, cell cycle
progression, chromatin modification, and transcriptional inhibition and activation. In
DNA repair, Menin interacts with replication protein A2 (RPA2), a subunit of RPA
which binds to ssDNA and is involved in ATR (ataxia telangiectasia and Rad3 related)mediated sensing of DNA damage. However, how Menin regulates RPA2 is unknown as
RPA2 still binds to ssDNA at normal levels (Gallo et al., 2010; Sukhodolets et al., 2003).
Menin also binds and promotes FancD2 (fanconi anemia, complementation group D2)
function, a protein required in promoting the BRCA1 (breast cancer 1, early onset)mediated DNA repair pathway (Garcia-Higuera et al., 2001; Jin et al., 2003). Menin
itself is also stabilized by phosphorylation during DNA damage but during
tumourigenesis (specifically pancreatic ductal adenocarcinoma) menin expression and
promoter methylation is reduced (Cavallari et al., 2009; Francis et al., 2011; Shen et al.,
2009). In damaged or tumourigenic cells, menin may promote cell death through direct
repression of hTERT (human telomerase reverse transcriptase) transcription to suppress
maintenance of telomeres after cell replication (Blasco, 2005; Lin and Elledge, 2003).
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With cell cycle progression, studies show that Menin binds and suppresses transcriptional
activation mediated by activator S-phase kinase (ASK), a protein required for S-phase
entrance (Kumagai et al., 1999; Schnepp et al., 2004). Menin also recruits MLL (mixedlineage leukemia) in histone methyl transferase complexes (HMTC) which promotes
methylation of H3K4 and transcriptional activation of genes including p18, p27, and
TFF1 (trefoil factor 1), and regulates homeobox genes (HOX genes) either positively or
negatively depending on the tissue. Studies also show that Menin directly binds to the
promoters of these specific genes (Dreijerink et al., 2006b; Hughes et al., 2004; Milne et
al., 2002; Milne et al., 2005; Nakamura et al., 2002; Wu and Hua, 2011; Yokoyama et al.,
2004).

P27 and p18 are both CDK (cyclin-dependent kinase) inhibitors thereby

suppressing G1-phase progression and S-phase entrance (Agarwal et al., 2009; Milne et
al., 2005).

Menin, within this HMTC complex, also interacts with retinoblastoma

binding protein 5 (RbBP5) and the large subunit of RNA polymerase II (POLR2B,
polymerase (RNA) II (DNA directed) polypeptide B) promoting HMTC activity (Hughes
et al., 2004). Menin levels have been shown to correlate with and control the posttranslational

processing

of

the

hyperphosphorylated

(inactive)

form

of

the

Retinoblastoma protein (ppRb), thereby negatively affecting the anti-tumourigenic nature
of Rb in cell cycle progression and other Rb controlled processes (Ivo et al., 2011).
Within the HMTC, Menin may also bind to estrogen receptor alpha (ERα) in an estradiol
(E2) dependent manor, acting as a coactivator of ERα-mediated transcriptional activity
(ie. on the TFF1 promoter). Menin also binds TFF1 directly and the role of TFF1 is
tissue specific but may be involved with cell death, proliferation, and motility (Dreijerink
et al., 2006b; Ribieras et al., 1998).
Menin can also directly repress transcriptional activity mediated by an oncogene, JunD,
through prevention of phosphorylation and recruitment of mSin3A and histone
deacetylase complexes (HDAC), with menin binding to all three components (Agarwal et
al., 1999; Agarwal et al., 2003; Gallo et al., 2010; Gobl et al., 1999; Kim et al., 2003).
This menin-JunD interaction negates the oncogenic activity of JunD thereby repressing
proliferation (Agarwal et al., 2003).

Menin can suppress transcriptional activation

mediated by NFκB (nuclear factor of kappa light polypeptide gene enhancer in B-cells)
through binding to NFκB1, NFκB2, and RelA (v-rel reticuloendotheliosis viral oncogene
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Figure 1.3.

Menin Interactions Summary

This diagram summarizes the direct interacting partners of Menin and the effect of this
interaction on various cellular processes. Although there are other interacting partners of
Menin, only the ones discussed in the main text are shown. The thick connecting bars
illustrate an interaction whereby Menin positively (green) or negatively (red) affects the
activity and/or expression of that specific interacting partner. Thick gray bars indicate
that the interacting effect of Menin is unknown. The thin blue bars illustrate the effects
of this interaction on downstream cellular processes such that the interaction promotes
(arrow), inhibits (blunted line), or its effect on that process is unknown or variable within
cell types (line).

Connecting adjacent partners indicate an interaction and complex

formation; some components may not always be required depending on the cell type or
cellular process. Blue shapes not directly connected to Menin (but connected to a Menin
interacting partner) are required for Menin’s interacting effect on that partner.
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Figure 1.3.
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homolog A) subunits, thereby promoting apoptosis and repressing proliferation,
angiogenesis, and metastases (Escarcega et al., 2007; Heppner et al., 2001). Menin also
binds and enhances Smad3-mediated transcriptional activation through the TGFβ
(transforming growth factor, beta) pathway. This pathway is involved in repressing
proliferation, parathyroid hormone (PTH) secretion, prolactin expression, and is able to
repress menin as well (Balogh et al., 2010; Hendy et al., 2005; Kaji et al., 2001). Menin
can positively bind Smads 1 and 5 along with Runx2 (runt-related transcription factor 2)
to promote BMP (bone morphogenetic protein) signalling which enhances differentiation
but reduces proliferation (Kaji et al., 2001; Sowa et al., 2004). The Menin-Smad3
interaction is also able to repress the effects of the Menin-Smad1/5 interaction (Sowa et
al., 2004).
The canonical Wnt/β-catenin signalling pathway regulates a variety of cellular functions
including differentiation, proliferation, and cell adhesion.

Within this pathway, the

function of menin is variable such that menin is able to repress Wnt (wingless integration
1) signalling by binding and shuttling β-catenin out of the nucleus as well as stabilizing
membrane bound E-cadherin (Cao et al., 2009). However, studies show that menin also
promotes Wnt signalling by regulating H3K4 trimethylation and thus promotes Wnt
target gene, Axin2, expression (Chen et al., 2008).

Menin is also involved in the

PI3K/AKT pathways by binding to AKT1 and negatively regulating its activity by
preventing its translocation from the cytoplasm to the plasma membrane. This AKT1menin interaction reduces PI3K/AKT pathway signalling thereby leading to an increase
in apoptosis and reducing proliferation and cell growth (Wang et al., 2011). Another
interacting partner of menin is IGFBP2 (insulin-like growth factor binding protein 2)
where menin binds to its promoter, repressing IGFBP2 expression. IGFBP2 is involved
in proliferation but its regulatory effect varies between cell types (Yan et al., 2009).
Studies show that menin binds and promotes CASP8 (Caspase-8) expression and
IQGAP1 (IQ motif containing GTPase activating protein 1) functionality.

These

interactions promote apoptosis through CASP8, and through IQGAP1 promote
aggregation and suppress cell motility (La et al., 2007; Yan et al., 2009). There are still
additional partners of menin, however this summary describes the majority of wellknown direct interactions and their cellular effects.
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In addition, a study of menin function in melanoma tissue demonstrates the indirect
ability of menin to repress malignancy through regulating multiple pathways such that
tumourigenic cells present with reduced growth factor pleiotrophin, receptor protein
tyrosine phosphatase, PI3K (phosphoinositide 3-kinase), phosphorylated FAK (focal
adhesion kinase), and phosphorylated ERK 1/2 (extracellular-signal-regulated kinases,
also known as MAP kinase) (Gao et al., 2011).
Overall, menin is involved with numerous cellular pathways and interacting partners, all
of which act to suppress neoplastic formation, growth, and malignancy.

1.3.3

Menin in Rodent Development

Menin is found in a variety of species, all having a very similar homology to the human
encoded menin protein. For example, Menin found in mice display a 96.6% homology to
that found in humans, rats exhibit 97% homology, and zebrafish are 75% homologous
(Biondi et al., 2004; Khodaei et al., 1999; Maruyama et al., 1999). For this reason, the
mouse has been a common test model for localization and functional studies of Menin.
Stewart and colleagues in 1998 reported that murine Men1 is found by 7 days of gestation
and at embryonic day 13.5 (e13.5) in the forelimb, gut, head, heart, and lung. By e14
Men1 is highly expressed throughout the developing embryo and later becomes restricted
to certain cells within various adult tissues throughout the body (Stewart et al., 1998).
Interestingly, homozygous Men1 null mice show no gross abnormalities at e9.5 but die in
utero by e11.5-12.5 which allowed researchers to study which systems and organs have
been affected or underdeveloped (Crabtree et al., 2001).

Analysis of those studies

provided evidence that Menin is required for development of the neural tube (central
nervous system), heart (differentiation of certain cardiac cells), liver (differentiation of
hepatoblasts), and the endocrine pancreas (Bertolino et al., 2003a; Fontaniere et al.,
2008).

Table 1.1 summarizes the Menin knockout mouse and cell culture models.

Heterozygous Men1 mice exhibit similar characteristics of the MEN1 disease but not
until 9 months of age (9 m) where they begin to develop hyperplastic pancreatic islets,
Insulin-secreting islet tumours (at slightly lower levels per islet), and display increased
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vascularization (Crabtree et al., 2001). Studies show that Menin may also be involved in
differentiation through the retinoic acid (RA) pathway since RA induces Menin
expression and Menin induces RA and RA receptors (Kanungo and Chandrasekharappa,
2012). A study using embryoid bodies (EBs) formed by differentiating wild-type and
Men1-/- embryonic stem (ES) cells gave further insight into Menin’s role in development.
Results showed a probable hemoglobinization deficiency with the following RNA
alterations at e8: reduced Runx2, Postn, and Msx2 (osteoblast differentiation genes); KDR
(a VEGF receptor, endothelial cell proliferation and differentiation in the liver); Hoxa9 (a
myeloid and lymphoid development gene); and Kit1 (a hematopoietic growth factor and
an erythrocyte differentiation gene). Genes involved in pancreatic development that were
reduced included Sox4, Foxa1, Btc, Igf2, Nfatc1, Wnt5a, Wisp1, and cell cycle controls
cyclinG2 and cdkn1c (Zhang et al., 2007).

1.3.4

Menin in Rodent Pancreatic Development & Function

Looking more closely at the developing rodent pancreas, one can gather some
information regarding the function of Menin through development. It has been found to
be expressed at each stage e11.5-e18.5 in the entire pancreatic epithelium, and at e16.5 it
is found in Insulin+, Glucagon+, and Mucin1+ ductal cells (Fontaniere et al., 2008). It is
important to note that Menin is not required for pancreatic bud formation. Analysis of
the pancreas of homozygous Men1-/- mice just before lethality at e12.5 (1st transition,
appearance of endocrine progenitors) has revealed a reduced number of Glucagon+ cells
and an increase in apoptosis (Fontaniere et al., 2008). This suggests that Menin is
required to support differentiation or survival (by repressing apoptosis) of Glucagon+
cells at this stage, but this requirement is not absolute (Fontaniere et al., 2008). See
Table 1.1 for a detailed list of menin mouse and cell culture models and their
corresponding results.

Cultured pancreatic cells reminiscent of the 2nd transition of

development (e12.5 + 7 days culture) showed a significant decrease in Insulin+ cells but
no change in exocrine cells. This indicates that Menin is involved in the endocrine but
not exocrine development of the pancreas. Cystic structures also formed in the cultured
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Table 1.1: Summary of Mouse and Cell Culture Menin Knockout Models
Model

Knockout
Conditions

Global Effects

Pancreatic Effects

Men1-/mice

Global knockout

-die in utero e11.5-e12.5

-↓ Glucagon+ cells

-neural tube, heart, liver, and
pancreas organogenesis

-↑ Apoptosis

Men1-/culture

Cultured Men1-/mouse
pancreatic cells
(7 days)

-N/A

-↓ Insulin+ cells
-↓ Ngn3+ cells
-exocrine unchanged
-cystic structures

Men1-/+
mice

Global knockout

-no development effect

-no developmental
effect
-MEN1 at 9 m
(hyperplastic islets,
insulinomas, increased
vascularization)

Men1-/EBs

Differentiated
ES cell knockout
(Cell culture)

-hemoglobinization deficiency

-Sox4, Foxa1, Btc, Igf2,
-genes relating to development Nfatc1, Wnt5a, Wisp1
and cell cycle controls
of osteoblasts, endothelial
cyclinG2 and cdkn1c
cells (liver), myeloid and
lymphoid cells, hematopoietic -↓ Nkx2.2
stem cells and erythrocytes
-earlier Foxa2 and
Sox17 expression
(endodermal
differentiation markers)

Men1F/FRipCre+
mice

Insulin directed
beta-cell
knockout

-no developmental effect

Men1F/FPdx1Cre+
mice

Pdx1 directed
beta-cell
knockout

-no developmental effect

-no developmental
effect
-insulinomas by 2 m
(MEN1)
-no developmental
effect
-insulinomas by 3 m
(MEN1)
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cells which suggest that Menin prevents abnormal endocrine or ductal differentiation.
Also, the number of Ngn3+ cells was decreased which could lead to the observed
decrease in endocrine+ cells. Menin could therefore be regulating Ngn3 expression or the
formation of Ngn3+ cells which regulates the amount of endocrine cells in the pancreas
(Fontaniere et al., 2008). In a beta-cell specific knockdown (Men1F/F-RipCre+) mice,
Menin showed consistently reducing expression levels from e11 and mice consequently
developed islet tumours by 2 m (Men1-/- cells) suggesting a shorter latency period than
heterozygous mice (Bertolino et al., 2003b).

A Pdx1 directed Men1 inactivation

(Men1F/F-Pdx1Cre+) showed no effect on pancreatic development with low Menin levels
(measured at 2 m) and characteristics of insulinoma formation by 3 m, thus confirming
the requirement for Menin tumour suppression and suggesting a possible threshold effect
of Menin expression during development (Shen et al., 2009). Looking at Men1 null EBs
specifically in pancreatic development, genes Sox4, Foxa1, Btc, and Igf2 were downregulated (Zhang et al., 2011; Zhang et al., 2007).

Results also showed varying

transcription factor expression levels from e3-7 and stabilizing by e9 except for a
significant reduction in Nkx2.2 at e9-10 suggesting a possible dedifferentiation process
with the lack of Nkx2.2. Also, endoderm markers Foxa2 and Sox17 showed an earlier
expression suggesting that null EBs preferentially initiate differentiation along the
endodermal pathway (Zhang et al., 2011). However, overexpression of Menin can also
induce endodermal differentiation independent of RA (Kanungo and Chandrasekharappa,
2012).
In the adult pancreas, studies show that menin is not only involved in tumour suppression
and proliferation but also in insulin secretion, cell motility, and adhesion (Fontaniere et
al., 2008). Within beta-cell compensatory situations such as pregnancy and obesity,
menin is repressed to allow for proliferation and the subsequent increase in beta-cell mass
(Karnik et al., 2007). This compensatory process of increasing beta-cell mass balances
out the increased demand for insulin. In adult rat islets, the presence of Menin inhibits
Insulin promoter activity and its ability to respond to Glucose induction, an important
feature in development and a model of hypersecretion for insulinomas (Sayo et al., 2002).
Insulin and Glucose have both been shown to reduce Menin expression and cytoplasmic
localization via the PI3K/AKT/FoxO1 pathway. FoxO1 is able to bind Menin to reduce
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its expression but Menin is also able to reduce FoxO1 activity at the same time
(Wuescher et al., 2011; Zhang et al., 2012). Another feature of menin includes its ability
to interact with IQGAP1 in the adult pancreas, a scaffold protein regulating cell motility
and adhesion. This Menin-IQGAP1 interaction is able to promote islet aggregation and
may be a crucial component in islet development (Yan et al., 2009).
Overall, Menin seems to have a dual functionality, one to promote endocrine (including
progenitor) differentiation and survival and the other in the fully developed pancreas to
suppress proliferation and insulin hypersecretion and to promote aggregation (Fontaniere
et al., 2008).

1.4

Project Rationale and Outline

To date, most human menin research has focused on the clinical neoplastic aspect of
menin within the MEN1 disease and knowledge on the functional role of MEN1/menin
during human fetal pancreatic development is limited. Previous studies have implicated
Menin as an essential protein for rodent pancreatic development and have suggested that
its action in pancreatic progenitor cells is through Ngn3 regulation. In this study I hope
to take the knowledge of its role in proliferation and rodent pancreatic development to
determine if this phenomenon is recapitulated in human pancreatic development to
further elucidate its functional significance. Understanding how menin interacts with
other factors involved in pancreatic development and their functional significance during
proliferation and differentiation in the human fetal pancreas, is crucial to the
understanding of human pancreatic endocrine development. This novel knowledge will
aid in furthering developmental studies and advancing islet generation studies for diabetic
cell-based therapies (Gupta V, 2002; Jeon et al., 2009; Kim and Hebrok, 2001).
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Objective
To examine the expression pattern and functional roles of menin during human fetal islet
development through its association and interaction with other necessary transcription
factors.
Hypothesis
Menin is required for islet differentiation by regulating islet progenitor proliferation and
the expression of NGN3 and other essential pancreatic transcription factors in the
developing human pancreas.
Specific Questions
1. What is the spatial and temporal expression pattern of menin throughout human
pancreatic development?
2. What developmental transcription factors are co-localized with menin in the
developing human fetal pancreas?
3. What is the relationship between proliferating cells and menin+ cells in the
developing human fetal pancreas?
4. Does downregulation of MEN1 in islet-epithelial cell clusters affect endocrine cell
proliferation and differentiation?
5. Does overexpression of MEN1 in islet-epithelial cell clusters affect endocrine cell
proliferation and differentiation?
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Chapter 2

Research Design and Methods
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Chapter 2 – Research Design and Methods
2.1

Pancreatic Tissue Collection

Human fetal pancreata were collected from 8 to 21 weeks of fetal age in accordance with
protocols approved by the Human Health Sciences Research Ethics Board at the
University of Western Ontario (Appendix I) and guidelines from the Canadian Council
on Heath Sciences Research Involving Human Subjects. The fetal age is typically two
weeks less than the gestational age (based on the menstrual cycle), to account for the two
pre-ovulation weeks that precede conception. Pancreatic tissues were dissected and
washed with sterile phosphate buffered saline (PBS) and immediately processed for
either RNA and/or protein extraction, fixation for immunofluorescence, or for isletepithelial cell cluster isolation as described below.

2.2

Immunofluorescence & TUNEL Assay

To determine menin expression patterns and co-localizations in the developing human
pancreas, whole human fetal pancreata were collected at three 3 developmental stages 812 weeks (1st trimester), 14-16 weeks (early 2nd trimester), and 18-21 weeks (later 2nd
trimester) of fetal age and fixed in 4% paraformaldehyde (PFA) (Fisher Scientific
Company; Ottawa, ON, Canada) overnight at 4°C. Samples were washed in 1xPBS and
processed using a standard protocol of dehydration and paraffin embedding with an
automated tissue processing and embedding machine (Shandon CitadelTM Tissue
Processor, Citadel 1000, Thermo Electron Corporation; Waltham, Massachusetts, USA).
Pancreatic sections were cut at 4 μm thickness using a microtome (Leica RM2245,
Vashaw Scientific Inc.; Norcross, GA, USA) through the entire length of the pancreas.
Prior to immunostaining, paraffin sections were deparaffinized in xylene and rehydrated
with decreasing ethanol concentrations (100%, 90%, and 70%), rinsed in distilled H2O
(dH2O) and washed with 1xPBS.

Heat-induced antigen retrieval was used on all

pancreatic sections by immersing the slides in boiling citrate-based antigen retrieval
buffer (pH 6.0) and heating at medium to high power (70%) for 20 minutes using a

33
microwave (Amana 1000 Watt Commercial microwave). Slides were then cooled to
room temperature (approximately 1 hour), rinsed in dH2O, and washed with 1xPBS.
Nonspecific binding was blocked with 10% normal goat serum diluted in blocking buffer
at room temperature for 30 minutes in a humidity chamber. Blocking serum was tapped
off and slides were incubated with appropriate dilutions of primary antibodies as listed in
Table 2.1 overnight at 4°C in a humidity chamber (Lyttle et al., 2008). The next
morning, sections were washed in 1xPBS, and incubated with appropriate dilutions of
fluorescein-conjugated secondary antibodies as listed in Table 2.1 for 1 hour at room
temperature.

Secondary antibodies were obtained from Jackson Immunoresearch

Laboratories (West Grove, PA, USA). Slides were washed in 1xPBS before a nuclei
counterstain, 4’-6’-diamidino-2-phenylindol (DAPI) (Sigma; St Louis, MO, USA), was
applied to the slides at a 1:2000 dilution in PBS. Negative controls for the anti-menin
antibody were performed with the omission of either primary or secondary antibodies as
shown in Appendix II: Supplementary Figure 1.
Cell death was determined with TUNEL labeling using the In Situ Cell Death Detection
Kit by Roche Applied Science (Penzberg, Germany) where the terminal deoxynucleotidyl
transferase is conjugated with fluorescein-dUTP at the 3′-end. This kit was used
according to the manufacturer’s instructions with a 1:20-40 dilution of TUNEL labeling
enzyme (Saleem et al., 2009).

2.3

Morphometric Analysis

Images of immunostained sections were acquired using a Leica DMIRE2 fluorescence
microscope (Leica Microsystems; Bannockburn, Il, USA) and a digital camera (Retiga
1300, High-sensitivity IEEE 1394 FireWireTM digital camera, QIMAGING; Burnaby,
British Colombia, Canada) connected to a Macintosh computer. Openlab image software
(Improvision; Lexington, MA, USA) was used to capture, store, and export the images.
Velocity LE and Velocity Demo imaging software (PerkinElmer, Waltham, MA, USA)
were used to store and analyze images.
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Table 2.1: List of Antibodies/Antisera for Immunofluorescence and Western-Blot
Analyses
Primary antibody
mouse monoclonal Amylase

Dilution
1:50

Company, Location
Santa Cruz Biotech., Santa Cruz,
CA, USA

mouse monoclonal Calnexin

1:2000a

BD Biosciences, Mississauga, ON,
Canada

a

rabbit polyclonal Caspase-3

1:1000

Cell signaling, Danvers, MA, USA

rabbit polyclonal Cleaved Caspase-

1:200

Cell signaling, Danvers, MA, USA

mouse monoclonal Cytokeratin 19

1:50

Dako, Mississauga, ON, Canada

rabbit polyclonal Cytokeratin 19

1:200

Abcam Inc, Cambridge, MA, USA

mouse monoclonal Glucagon

1:2000

Sigma, St. Louis, MO, USA

rabbit polyclonal Glucagon

1:50

Santa Cruz Biotech., Santa Cruz,

3 (Asp175)

CA, USA
mouse monoclonal Insulin

1:1000

Sigma, St. Louis, MO, USA

rabbit polyclonal Insulin

1:50

Santa Cruz Biotech., Santa Cruz,
CA, USA

mouse monoclonal ISL1

1:200

DSHB, University of Iowa, Iowa
city, USA

mouse monoclonal KI67

1:100

BD Biosciences, Mississauga, ON,
Canada

rabbit polyclonal KI67

1:200

Abcam Inc, Cambridge, MA, USA

rabbit polyclonal Menin/MEN1

1:300-4000a

Bethyl Lab Inc., Montgomery, TX,
USA

mouse monoclonal NGN3

1:100

DSHB, University of Iowa, Iowa
city, USA

mouse monoclonal NKX 2-2

1:200

Gift-Dr.Wright, University of
Vanderbilt, Nashville, TN, USA

mouse monoclonal NKX 6-1

1:100

DSHB, University of Iowa, Iowa
city, USA
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guinea monoclonal PDX-1

1:1000

Gift-Dr.Wright, University of
Vanderbilt, Nashville, TN, USA

rabbit polyclonal

1:50

Zymed, San Francisco, CA, USA

rabbit polyclonal Somatostatin

1:50

Zymed, San Francisco, CA, USA

rat monoclonal Somatostatin

1:50

Abcam Inc, Cambridge, MA, USA

mouse monoclonal Sox9

1:100

Novus Biologicals, LLC Littleton,

Pancreatic Polypeptide

CO, USA
rabbit polyclonal Sox9

1:50-1000a

Santa Cruz Biotech., Santa Cruz,
CA, USA

Secondary antibodies
Goat anti-mouse

1:100

JRL; West Grove, PA, USA

Goat anti-rabbit

1:100

JRL; West Grove, PA, USA

Goat anti-guinea pig

1:100

JRL; West Grove, PA, USA

Goat anti-rat

1:100

JRL; West Grove, PA, USA

a

dilution factor applied for western blot analysis. DSHB, Developmental Studies

Hybridoma Bank; JRL, Jackson Immunoresearch Laboratories
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To determine the percentage of cells expressing nuclear menin (nMenin) in the ductal,
endocrine,

and

PDX1+

cell

populations

at

any

given

time

point,

double

immunofluorescence staining for nMenin with CK19 (ductal), insulin, glucagon, or
PDX1 was performed and double positive cells were counted. To determine the colocalization of nMenin in the proliferating cells, double labelled nMenin and KI67 cells
were imaged and counted. For cell counting analysis, ten fields from the head to the tail
of each pancreas were randomly imaged with a minimum of three pancreata per age
group (Al-Masri et al., 2010). At least 1500 cells per ductal region (CK19+), 500 cells
per endocrine region (insulin+, glucagon+), and 500 cells for each PDX1+ and KI67+ cell
populations were counted per pancreata and the data was expressed as a percentage.

2.4

Isolation of Islet-Epithelial Cell Clusters

Human fetal pancreata from ages 15 to 19 weeks of fetal age were selected since this is a
period in the second trimester where there is a significant increase in beta-cell
differentiation and function.

As well, NGN3 expression decreases as development

proceeds and so a time period in the middle of development (since earlier 8-12 wks is not
possible due to sample availability) is optimal for characterization of the involvement of
menin in NGN3 expression and islet differentiation (Lyttle et al., 2008). 15-19 wk
pancreata were collected and immediately dissected (as in Section 2.1) from surrounding
tissue and digested with a collagenase dissociation buffer (collagenase V, 1 mg/mL
[Sigma]; 1xHBSS, 500 mL [Sigma]; HEPES, 25 nM [Sigma]; DNaseI [Roche]) for 30
min in a 37°C water bath. Residual enzyme was removed with wash buffer (1x HBSS)
and the remaining cells, termed islet-epithelial cell clusters, were comprised mainly of
undifferentiated epithelial cells (CK19+ cells, most of which expressed PDX1), endocrine
cells (~7-10%), and exocrine cell markers (~8%) (Li et al., 2006). Cell clusters were
immediately plated and cultured as described below.
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2.5

Transfection of Islet-Epithelial Cell Clusters with MEN1 siRNA

Isolated islet-epithelial cell clusters were plated at 1-5x104 cells/well in a 12-well plate
cultured with 600 uL/well of CMRL 1066 plus 10% fetal bovine serum (FBS, Invitrogen;
Burlington, ON, Canada).

After a 24 hr recovery and adhesion culture, cells were

transiently transfected with 53 nM menin siRNA (human, sc-35922) (MEN1-siRNA) or
control siRNA (sc-37007, proprietary sequence, Ctrl-siRNA) commercially produced by
Santa Cruz Biotechnology Inc. using a siRNA transfection kit (Santa Cruz; CA, USA)
according to manufacturer’s instructions. A pool of two target-specific sequences for
human menin siRNA, as listed in Table 2.2, was used with a minimum of 3 to 6
individual pancreata per experimental group. Following a 24, 48, and 72 hr transfection
period,

islet-epithelial

cell

clusters

were

harvested

and

processed

for

immunofluorescence, RNA isolation, or protein analysis to determine knockdown
efficiency (Al-Masri et al., 2010).

2.6

Transfection of Islet-Epithelial Cell Clusters with MEN1 Overexpression
Vector

Isolated islet-epithelial cell clusters were plated at 1-5x104 cells/well in a 12-well plate
using 600 uL/well of CMRL 1066 supplemented with 10% FBS. After a 24 hr recovery
period, cells were washed with CMRL 1066 supplemented with 1% Bovine Serum
Albumin (BSA, Sigma) and fresh CMRL 1066 – 1% BSA was added as per transfection
protocol requirements. The cells were then transiently transfected with 1 μg/well of either
the pEGFP-N2 vector with a human full-length MEN1 cDNA insertion (N2-M1) or a
control pEGFP vector (Ctrl-EGFP); both gifts from Dr. Xiaoying Li, (Cao et al., 2009).
LipofectamineTM 2000 diluted in CMRL 1066 – 1% BSA was used for transfection
according to manufacturer’s instructions (Invitrogen). Following a 48 hr transfection
period,

islet-epithelial

cell

clusters

were

harvested

and

processed

for

immunofluorescence, RNA and/or protein extraction with at least 5-6 repeats per
experimental group.
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Table 2.2: Menin siRNA (h) Sequences; A Pool of 2 Different siRNA
Duplexes (sc-35922)*
Sequence

Sense

Antisense

sc-35922A

CUCUUCAGCUUCAUCACAGtt

CUGUGAUGAAGCUGAAGAGtt

sc-35922B

AGAUGGAGGUGGCGUUCAUtt

AUGAACGCCACCUCCAUCUtt

no.

*Santa Cruz Biotechnology, Santa Cruz, CA, USA
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2.7

Immunofluorescence of Islet-Epithelial Cell Clusters

Following transfection, islet-epithelial cell clusters were harvested, washed in 1xPBS,
and fixed in 4% PFA overnight at 4°C.

The cells were washed in 1xPBS again,

embedded in 2% agarose before paraffin embedding (Li et al., 2006), and sectioned as
outlined in section 2.2 (Immunofluorescence & Morphometric Analysis). Sections were
cut vertically through the pellet until a minimum of 1000 cells were present per section.
Staining and analysis were performed as outlined in section 2.2.

2.8

Protein Extraction & Western Blot Analysis

To determine the protein levels of total menin, signalling molecules and transcription
factors in the developing human pancreas, and in islet-epithelial cell clusters following
various experimental treatments, proteins from human fetal pancreata and cultured cells
were

extracted

by

incubation

in

Nonidet-P40

lysis

buffer

(Nonidet-40,

phenylmethylsulfonyl fluoride, sodium orthovanadate [Sigma]; complete inhibitor
cocktail tablet [Roche]) for 20 minutes on ice. Tissue was dispersed by sonication on ice
where for whole tissue this was performed 10-20 sec (5-10 times), and for cell clusters
the duration was 5 sec (10 times) with a 30 sec cool down in between each sonication
time. Cell debris was then separated from the protein by centrifugation at 12,000 rpm for
20 min in the cold room at 4°C and extracted protein (supernatant) was then stored at 80°C for future use (Al-Masri et al., 2010; Li et al., 2006; Saleem et al., 2009). Protein
concentration was measured with the Bradford dye assay (BioRad Laboratories;
Mississauga, ON, Canada) and analysed with a Multiskan® spectrum spectrophotometer
(Thermo Scientific; Vantaa, Finland).
Western blotting was performed by equal loading of lysate protein: pancreata 30 μg and
cells 15-25 μg. Protein was separated using 10% (or 12%) sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose
membrane (Bio-Rad) by electroelution. Protein was transferred using either the TransBlot SD Semi-Dry Transfer Cell at 20 V for 30 minutes or the Transblot Electrophoretic
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transfer cell at 250 mA for 2.5 hrs (BioRad). For each transfer, a sandwich (sponge –
filter paper – membrane – gel – filter paper – sponge) was assembled. Transferred
protein was visualized with 0.2% Ponceau S. Membranes were washed in 1xTBST (Trisbuffered saline with 0.1% Tween 20), and incubated overnight at 4°C in a 5% Non-Fat
Dairy Milk blocking solution. Membranes were incubated with appropriate primary
antibody dilutions (Table 2.1) for 2 hrs at room temperature followed by washing
3x10min with 1xTBST. Appropriate dilutions of corresponding anti-rabbit or anti-mouse
conjugated IgG secondary antibodies conjugated to horseradish peroxidise (Cell
Signalling, Danvers, MA, USA) were added and incubated for 1 hr at room temperature
(Al-Masri et al., 2010; Li et al., 2006; Saleem et al., 2009). Proteins were detected using
enhanced chemiluminescent (ECL™-Plus Western blot) detection reagents (Perkin
Elmer) and visualized using the Versadoc 5000MP imaging System (Bio-Rad) and
Quantity One software (Bio-Rad). Densitometry was performed using Image Lab 3.0
software (Bio-Rad) and normalized to a loading control. A western blotting menin
antibody control was performed with the omission of either primary or secondary
antibodies as shown in Appendix II: Supplementary Figure 2.

2.9

RNA Extraction & Quantitative Real-Time RT-PCR (qRT-PCR) Analysis

Total RNA was extracted from pancreatic tissues using TRIZOL reagent (Invitrogen)
(performed by Jinming Li previously in the lab) and from islet-epithelial cell clusters
using the RNAqueous-4PCR kit by Ambion (Austin, TX, USA) according the
manufacturer’s instructions, which also included a DNase I treatment step (Li et al.,
2006; Wang et al., 2005). RNA concentration was measured by diluting 1 μL of sample
in 250 μL of DEPC (Diethylpyrocarbonate) water in a 96-well plate in duplicate. The
Multiskan® spectrum spectrophotometer was used to measure O.D260 (total RNA
concentration) and the corrected OD ratio of A260/A280 (RNA purity). Electrophoresis
with a 1% agarose gel was run to determine RNA quality using ethidium bromide
staining (Appendix II: Supplementary Figure 3).
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Real-time RT-PCR reactions were performed by Jinming Li according to the following
protocol. For each RT reaction mixture the following components were added: 2 μg of
RNA, 1 μL random hexamers (300 ng/mL), 1 μL Oligo-dT, and DEPC water until a total
volume of 10.5 μL was reached. Tubes were then heated in the Chromo4 Real-Time
PCR machine (Bio-Rad) for 10 min at 72°C and cooled for 5 min at 4°C (Lyttle et al.,
2008; Wang et al., 2005). For each reaction mixture the following master mix was
added: 4 μL of buffer, 2 μL of DTT, 2 μL of 10 mM dNTP, and 0.5 μL of Rnasin. Tubes
were placed in the PCR machine, when 42°C was reached the machine was opened and
0.8 μL of Gibco BRL Superscript RT enzyme was added to each tube, and the machine
was resumed at the following settings: 42°C for 90 min, 94°C for 5 min, and 4°C for 60
min. Samples were then removed and double dH20 was added for a final concentration of
6 μg/80 μL, then aliquoted into 2 tubes and stored at -20°C.

Real-time PCR was

performed using the iQ SYBR Green Supermix kit in Chromo4 Real-time PCR (Bio-Rad)
with the following mixture: 12.5 μL of iQ SYBR Green Supermix, 2 μL of Primer 1, 2
μL of Primer 2, 2.5 μL of sterile water, and 6 μL of DNA template for a total volume of
25 μL (Lyttle et al., 2008). The PCR primers used are listed in Table 2.3. Relative gene
expression was calculated using the arithmetic formula “2-CT” where

C

T is the

difference between the threshold cycle of a given target cDNA and the internal standard
gene 18S rRNA subunit cDNA (Lyttle et al., 2008; Wang et al., 2005). This was
performed with at least 5 repeats per experimental group. The melting curves were used
to indicate if the qRT-PCR assays had specifically amplified target sequences (Appendix
II: Supplementary Figure 4). Controls involved omitting reverse transcriptase, cDNA,
or DNA polymerase and showed no reaction bands (Wang et al., 2005).

2.10

Statistical Analysis

Data was plotted and analysed using GraphPad Prism 5 statistical software (GraphPad
Software; La Jolla, CA, USA) which calculated mean, standard error, and statistical
analysis. Significant difference was determined using the paired student’s t-test or one-
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way ANOVA (analysis of variance) followed by the post hoc Bonferoni correction. Data
was expressed as means + SEM and considered statistically significant if p<0.05.

2.11

Collaboration Within This Study

Within this study, more than 80% of experimental techniques and analyses were
performed by myself with the following collaborations. Dr. Rennian Wang performed
pancreata collection, qRT-PCR data analysis, and aided with pancreatic dissections. Ex
vivo pancreatic processing (RNA extraction, protein extraction, and fixation for
immunofluorescence (IF)) was performed by Jinming Li along with ex vivo tissue section
preparation for IF.

Jinming Li also designed RNA primers, performed qRT-PCR

reactions, and aided with paraffin sectioning, NGN3 IF staining, and TUNEL labelling.
For western blotting; protein concentration and gel loading were performed with the aid
of Zhi Chao Feng (PhD student).
Please note that in vitro islet-epithelial cell cluster MEN1-siRNA and N2-M1
experiments were repeated by separate researchers (Dr. Rennian Wang and Jinming Li
exclusively) with n=3 for all groups (data not shown). Their results confirmed the data
described in this study.
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Table 2.3: Sequences of Real-time PCR Primers
Primer
Name

Accession
Number &
Definition

Primer Pair Sequence 5’----3’
(Sense/Antisense)

Location
(nt)

CDKN1A
(p21,
Cip1)

NM_000389.4 GGC TCC TTC CCA TCG CTG TCA

991-1011

TCA CCC TGC CCA ACC TTA GAG

1170-1150

CDKN1B
(p27,
Kip1)

NM_004064.3 AAG ATG TCA AAC GTG CGA GT

CDKN2C
(p18)

470-489

CGG GTT AAC TCT TCG TGG TC

600-581

NM_001262.2 CGG CGA CTC TCC CTA CTC AG

483-502

GAG TGA TGC GGA AAG CGT CT

108-127

CGC TTG TCC TCG TTC ATC TG

254-235

MEN1

NGN3

NM_005524.2 GTC AAC ACG ACA CCG GATAAA

297-317

AGT GCG CAC CTC GGT ATT AAC

647-627

NM_000244.2 TGT CAA CCG CGT CAT CCC TA

NKX2-2

394-375

NM_020999.2 AGC CGG CCT AAG AGC GAG TT

363-382

NM_002509.2 CGG GCC GAG AAA GGT ATG GA
CCG AGC TGT ACT GGG CGT TGT

NKX6-1

NM_006168.1 AGA CCC ACT TTT TCC GGA CA
CCG CTG CTG GAC TTG TGC TT

PDX-1

SOX9

18S

257-276

GCG GTG AAG CGG GCA TAG AG

TTG GTG AGC TTC GCG TCG TC

916-935

724-743

147

351

138

158

202

335

1058-1039

CCG AGT AAG AAT GGC TTT ATG

1411-1394

M11188.1

248

1117-1097

1262-1282

ACA AGA AGG ACC ACC CGG
ATT A
AGC TCG CCG ATG TCC ACG TCG
C

131

520-501

NM_000209.3 CTC CTA CAG CAC TCC ACC TTG

NM_000346.2

180

731-702

GCG
NM_002054.2 CAT TTA CTT TGT GGC TGG AT
(Glucagon)

HES1

Fragment
Size (bp)

866-887

153

323

1205-1184

GTA ACC CGT TGA ACC CCA TTC

1577-1597

CCA TCC AAT CGG TAG TAG CG

1729-1710

153
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Chapter 3 – Project Results
3.1

Menin Expression Pattern Throughout Human Fetal Pancreatic
Development

To examine the spatial and temporal expression pattern of menin throughout human
pancreatic development, pancreata were collected from 8 to 21 weeks of fetal age, and
were categorized into three developmental time points. Pancreata from 8-12 wks consist
of numerous undifferentiated PDX1+ ductal cells with few scattered single endocrine
cells and rare small islet clusters. During the 14-16 wk time point, islet clusters assemble
such that pancreata exhibit numerous small vascularized islet clusters, while pancreata
from 18-21 wks consist of adult-like islets with a rich vascular network (Lyttle et al.,
2008). Using a qRT-PCR approach, we first analyzed the expression of MEN1 mRNA
and demonstrated relative constant expression of MEN1 through 8-21 weeks of fetal age
in the developing human pancreas (Figure 3.1A). Western blot analysis revealed no
significant changes in total menin protein expression throughout development however a
slightly higher expression was noted at 8-12 wks (compared to 14-21 wks) (Figure
3.1B).
Since menin can be a nuclear or cytoplasmic protein, our experiments were performed
focusing on nuclear menin localization (nMenin) as opposed to cytoplasmic or total
menin analysis. This was to focus on the localization where menin is more likely to exert
its function, within the nucleus.
nMenin protein localization was analyzed in each pancreatic cell compartment using
double immunofluorescence staining at each developmental period from 8-21 wks. The
expression of nMenin was found to be highly detectable (>70%) within pancreatic
endocrine cells (insulin+ and glucagon+) from the earliest developmental stage studied (8
wks) with no significant changes through the 1st and 2nd gestational trimester (Figure 3.2;
Figure 3.3). Morphometric analysis within the ductal epithelium (CK19+) revealed a
high proportion of nMenin+ cells (>70%) in both the 8-12 wk and 18-21 wk
developmental periods with a significant reduction during the 14-16 wk developmental
stage (p<0.05 vs. 8-12 wks, p=0.06 vs.
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Figure 3.1.

Total MEN1 Gene and Protein Expression During Human Fetal

Pancreatic Development.
(A) Real-time RT-PCR analysis of MEN1 expression in human fetal pancreata during
three developmental stages (8-10 wks, 14-16 wks, and 19-21 wks), data are normalized to
8-10 wks (n=5 per age group).

(B) Western blot analysis of total menin protein

abundance (68 kDa) normalized to calnexin (90 kDa, loading control) in the developing
human fetal pancreas (n=3 per age group) (Wang et al., 2005). Data are expressed as
means ± SEM.
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Figure 3.2.

Co-localization of nMenin with Insulin During Human Fetal

Pancreatic Development.
Human fetal pancreata sections from three developmental time points (8-12 wks, 14-16
wks, and 18-21 wks) were co-immunolabelled with anti-menin and anti-insulin
antibodies, then visualized with Cy2 (green) and Cy3 (red) conjugated secondary
antibodies respectively. Nuclei were labelled with DAPI (blue). (A) A representative
section from 21 wks is shown where the top panel of images display double
immunostaining for menin (green), insulin (red), DAPI (blue), and an overlay of the
images. Scale bar corresponds to 25 micrometers. The bottom panel shows magnified
images corresponding to the boxed section in the above image. Arrows indicate a
nMenin+/insulin+ cell. (B) Quantitative analysis of co-localized nMenin+/insulin+ cells
relative to the total number of insulin+ cells (expressed as a percentage). Data were
determined by morphometric analysis and are expressed as means ± SEM (n=4 pancreata
per age group).
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Figure 3.3.

Co-localization of nMenin with Glucagon During Human Fetal

Pancreatic Development.
Human fetal pancreata sections from three developmental time points (8-12 wks, 14-16
wks, and 18-21 wks) were co-immunolabelled with anti-menin and anti-glucagon
antibodies then visualized with Cy2 (green) and Cy3 (red) conjugated secondary
antibodies respectively. Nuclei were labelled with DAPI (blue). (A) A representative
section from 20 wks is shown where the top panel of images display double
immunostaining for menin (green), glucagon (red), DAPI (blue), and an overlay of the
images. Scale bar corresponds to 25 micrometers. The bottom panel shows magnified
images corresponding to the boxed section in the above image. Arrows indicate a
nMenin+/glucagon+ cell. (B) Quantitative analysis of co-localized nMenin+/glucagon+
cells relative to the total number of glucagon+ cells (expressed as a percentage). Data
were determined by morphometric analysis and are expressed as means ± SEM (n=3-6
pancreata per age group).
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18-21 wks) (Figure 3.4). Furthermore, no difference in nMenin expression was observed
in somatostatin+ cells or in the exocrine (amylase+) compartment of the pancreas
throughout development (8-21 wks) (Figure 3.5).

3.2

Co-localization of Menin with Transcription Factors Throughout Human

Fetal Pancreatic Development
To further refine the expression pattern of menin throughout 8-21 weeks of fetal
development, we looked at the co-localization of a variety of transcription factors which
have been shown to be critical for human pancreatic development.

Using double

+

immunofluorescence and morphometric quantification, PDX1 cells, which indicate
undifferentiated pancreatic progenitors and later in development represent mature betacells, were first examined (Kim and Hebrok, 2001; Lyttle et al., 2008). Co-localization
of nMenin within PDX1+ cells was found throughout development with a significant
increase in co-localization in the 14-16 wk developmental stage (p<0.01 vs. 8-12 wks,
p<0.01 vs. 18-21 wks) (Figure 3.6). Co-localization of nMenin with SOX9 (Figure
3.7A), ISL1 (Figure 3.7B), NGN3 (Figure 3.8), NKX2.2 (Figure 3.9A) and NKX6.1
(Figure 3.9B) was found throughout development.

3.3

Expression of nMenin in Proliferating (KI67+) Cells in the Developing

Human Fetal Pancreas
Menin has been classically characterized as a tumour suppressor, a negative regulator of
cellular proliferation, in various endocrine tissues throughout the adult human body
(Chandrasekharappa et al., 1997). To examine the abundance of nMenin in proliferating
cells in the developing human fetal pancreas, the co-localization between nMenin and
proliferating (KI67+) cells was assessed using double immunostaining of whole human
fetal pancreata from 8-21 wks of fetal age (Figure 3.10A). Morphometric analysis
showed that cells expressing nMenin displayed a significant decreasing proliferation
capacity (KI67+) as development proceeded (p<0.05 8-12 wks vs. 14-16 wks, p<0.01
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Figure 3.4.

Co-localization of nMenin with CK19 During Human Fetal Pancreatic

Development.
Human fetal pancreata sections from three developmental time points (8-12 wks, 14-16
wks, and 18-21 wks) were co-immunolabelled with anti-menin and anti-CK19 antibodies
then visualized with Cy2 (green) and Cy3 (red) conjugated secondary antibodies
respectively. Nuclei were labelled with DAPI (blue). (A) A representative section from
21 wks is shown where the top panel of images display double immunostaining for menin
(green), CK19 (red), DAPI (blue), and an overlay of the images. Scale bar corresponds
to 25 micrometers. The bottom panel shows magnified images corresponding to the
boxed section in the above image.

Arrows indicate a nMenin+/CK19+ cell.

(B)

Quantitative analysis of co-localized nMenin+/CK19+ cells relative to the total number of
CK19+ cells (expressed as a percentage).

Data were determined by morphometric

analysis and are expressed as means ± SEM (n=3-6 pancreata per age group). *p<0.05.
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Figure 3.5.

Co-localization of nMenin with Somatostatin and Amylase During

Human Fetal Pancreatic Development.
Human fetal pancreata sections from 8-21 wks of fetal age were co-immunolabelled with
anti-menin and anti-somatostatin or anti-amylase bodies then visualized with Cy2 (green)
and Cy3 (red) conjugated secondary.

Nuclei were labelled with DAPI (blue).

Representative pancreatic sections are shown where the top panel of images display
double immunostaining for menin (green), (A) somatostatin or (B) amylase (red), DAPI
(blue), and an overlay of the images. Scale bars correspond to 25 micrometers. The
bottom panels show magnified images corresponding to the boxed section in the above
image. Arrows indicate a (A) nMenin+/somatostatin+ cell from 18 wk pancreata or a (B)
nMenin+/amylase+ cell from 21 wk pancreata.
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Figure 3.6.

Co-localization of nMenin with PDX1 During Human Fetal

Pancreatic Development.
Human fetal pancreata sections from three developmental time points (8-12 wks, 14-16
wks, and 18-21 wks) were co-immunolabelled with anti-menin and anti-PDX1 antibodies
then visualized with Cy2 (green) and Cy3 (red) conjugated secondary antibodies
respectively. Nuclei were labelled with DAPI (blue). (A) A representative section from
21 wks is shown where the top panel of images display double immunostaining for menin
(green), PDX1 (red), DAPI (blue), and an overlay of the images. Scale bar corresponds
to 25 micrometers. The bottom panel shows magnified images corresponding to the
boxed section in the above image.

Arrows indicate a nMenin+/PDX1+ cell.

(B)

Quantitative analysis of co-localized nMenin+/PDX1+ cells relative to the total number of
PDX1+ cells (expressed as a percentage).

Data were determined by morphometric

analysis and are expressed as means ± SEM (n=3-6 pancreata per age group). **p<0.01.
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Figure 3.7.

Co-localization of nMenin with SOX9 and ISL1 During Human Fetal

Pancreatic Development.
Human fetal pancreata sections from 8-21 wks were co-immunolabelled with anti-menin
and anti-SOX9 or anti-ISL1 antibodies then visualized with Cy2 (green) and Cy3 (red)
conjugated secondary antibodies.

Nuclei were labelled with DAPI (blue).

Representative pancreatic sections are shown where the top panel of images display
double immunostaining for menin (green), (A) SOX9 or (B) ISL1 (red), DAPI (blue), and
an overlay of the images. Scale bars correspond to 25 micrometers. The bottom panels
show magnified images corresponding to the boxed section in the above image. Arrows
indicate a (A) nMenin+/SOX9+ cell from 21 wk pancreata or a (B) nMenin+/ISL1+ cell
from 22 wk pancreata.
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Figure 3.8.

Co-localization of nMenin with NGN3 During Human Fetal

Pancreatic Development.
Human fetal pancreata sections from 8-21 wks were co-immunolabelled with anti-menin
and anti-NGN3 antibodies then visualized with Cy2 (green) and Cy3 (red) conjugated
secondary antibodies respectively.

Nuclei were labelled with DAPI (blue).

A

representative section from 21 wks is shown where the top panel of images display
double immunostaining for menin (green), NGN3 (red), DAPI (blue), and an overlay of
the images.

Scale bar corresponds to 25 micrometers.

The bottom panel shows

magnified images corresponding to the boxed section in the above image. Arrows
indicate a nMenin+/NGN3+ cell.
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Figure 3.9.

Co-localization of nMenin with NKX2.2 and NKX6.1 During Human

Fetal Pancreatic Development.
Human fetal pancreata sections from 8-21 wks were co-immunolabelled with anti-menin
and anti-NKX2.2 or anti-NKX6.1 antibodies then visualized with Cy2 (green) and Cy3
(red) conjugated secondary antibodies.

Nuclei were labelled with DAPI (blue).

Representative pancreatic sections are shown where the top panel of images display
double immunostaining for menin (green), (A) NKX2.2 or (B) NKX6.1 (red), DAPI
(blue), and an overlay of the images. Scale bars correspond to 25 micrometers. The
bottom panels show magnified images corresponding to the boxed section in the above
image. Arrows indicate a (A) nMenin+/NKX2.2+ cell from 20 wk pancreata or a (B)
nMenin+/NKX6.1+ cell from 21 wk pancreata.
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8-12 wks vs. 18-21 wks) (Figure 3.10B). Interestingly, 75-80% of proliferating KI67+
cells were positive with nMenin at 8-16 wks, but decreased significantly at 18-21 wks
(p<0.01 8-12 wks vs. 18-21 wks, p<0.01 14-16 wks vs. 18-21 wks). This indicates that
menin may play a role in proliferation during fetal pancreatic development where a
possible change of function may occur between 14-16 and 18-21 wks, as pancreatic cells
differentiate and mature (Figure 3.10C).

3.4

Downregulation of MEN1 Reduces Proliferation with No Effect on Endocrine
Population Levels

To examine the effects of MEN1 knockdown on human fetal pancreatic development,
islet-epithelial cell clusters were isolated from fetal pancreata aged 15-19 wks and treated
with control siRNA (Ctrl-siRNA) or MEN1-siRNA. This developmental period was
chosen due to sample availability and to optimize NGN3 expression, as this window of
development includes a major wave of endocrine development (Lyttle et al., 2008).
Knockdown efficiency was determined with siRNA transfection times of 24, 48, and 72
hrs using both qRT-PCR and double immunostaining approaches in order to reveal an
optimal knockdown time point (Figure 3.11).

Real-time RT-PCR analysis showed a

significant reduction of MEN1 mRNA at 48 hrs (p<0.05 vs. 48 hr Ctrl-siRNA) with no
change at 24 and 72 hrs (Figure 3.11A). The percentage of total nMenin+ cells was also
significantly reduced at 48 hrs post transfection (p<0.01 vs. 48 hr Ctrl-siRNA) (Figure
3.11B). A representative image illustrating the differences in nMenin staining between
control siRNA and MEN1-siRNA knockdown treatments at 48 hrs can be found in
Figure 3.12 where menin nuclear-stained cells are fewer and the reduction in intensity of
nuclear staining is apparent. The 48 hr time point was then chosen exclusively for
functional MEN1 knockdown analysis.
In adult endocrine cells throughout the body, including adult islets, menin has been
classically characterized as a negative regulator of proliferation (Chandrasekharappa et
al., 1997). To examine whether downregulation of MEN1 expression has an effect on the
proliferative capacity in the developing human fetal pancreas, proliferation of islet-
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Figure 3.10. Co-localization of nMenin with KI67+ Proliferating Cells.
Human fetal pancreata sections from three developmental time points (8-12 wks, 14-16
wks, and 18-21 wks) were co-immunolabelled with anti-menin and anti-KI67 antibodies
then visualized with Cy2 (green) and Cy3 (red) conjugated secondary antibodies
respectively. Nuclei were labelled with DAPI (blue). (A) A representative section from
20 wks is shown where the top panel of images display double immunostaining for menin
(green), KI67 (red), DAPI (blue), and an overlay of the images. Scale bar corresponds to
25 micrometers. The bottom panel shows magnified images corresponding to the boxed
section in the above image. Arrows indicate a nMenin+/KI67+ cell and arrow heads
indicate a KI67+ cell. (B) Quantitative analysis of co-localized KI67+/nMenin+ cells
relative to the total number of nMenin+ cells (expressed as a percentage).

(C)

Quantitative analysis of co-localized nMenin+/KI67+ cells relative to the total number of
KI67+ cells (expressed as a percentage). Data were determined by morphometric analysis
and are expressed as means ± SEM (n=3-6 pancreata per age group). *p<0.05, **p<0.01.
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Figure 3.11. Time Dependent Effect of MEN1 siRNA on MEN1 mRNA and
nMenin Expression in Islet-Epithelial Cell Clusters.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either control (Ctrl) or MEN1 siRNA and cultured for 24, 48, or 72 hrs.
(A) qRT-PCR analysis of total MEN1 mRNA levels at each transfection period for
control and MEN1 siRNA treatments. Data were normalized to 18S rRNA and are
expressed as means ± SEM where n=4-6 per experimental group. (B) Quantitative
analysis of the total number of nMenin+ cells in the islet-epithelial cell clusters of control
and MEN1 siRNA groups. Data were determined by morphometric analysis and are
expressed as means ± SEM where n=3-4 for each experimental group.
**p<0.01 vs. corresponding control siRNA treatment.

*p<0.05,
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Figure 3.12. Effect of MEN1 siRNA on nMenin Expression in Islet-Epithelial Cell
Clusters.
Representative images of islet-epithelial cell clusters isolated from human fetal pancreata
15 to 19 wks which were transfected with (A) control (Ctrl) siRNA or (B) MEN1 siRNA
at 48 hrs post treatment. Cells were harvested, paraffin-embedded, and sections were
immunolabelled with an anti-menin antibody visualized with a Cy2 (green) conjugated
secondary antibody. Nuclei were labelled with DAPI (blue). For each set, the top panel
of images shows staining for menin (green), DAPI (blue), and an overlay of images.
Scale bars correspond to 25 micrometers. The bottom panels show an enlargement of the
boxed section from the above image. Arrows indicate (A) a nuclear menin positive or
(B) a nuclear menin negative cell.
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epithelial cells (KI67 labelling index) was assessed in our MEN1-siRNA study using
immunofluorescence staining techniques. Morphological analysis revealed significantly
reduced total proliferation levels (KI67+ cells) in the MEN1-siRNA treated group (p<0.05
vs. Ctrl-siRNA) (Figure 3.13).
It was noted that there was no significant change in the proliferation of insulin+ cells, but
the proliferation capacity of glucagon+ cells was significantly reduced with MEN1
knockdown (p<0.05 vs. Ctrl-siRNA) (Figure 3.14A, D). However, there was no effect
on insulin and glucagon mRNA expression (Figure 3.14B, E) or the population levels of
insulin+ and glucagon+ cells (Figure 3.14C, F) with MEN1 and control siRNA
treatments. Somatostatin- and pancreatic polypeptide-expressing endocrine cells were
co-stained with KI67 as well and no observable difference was found in the proliferation
capacity of these cell types or the total quantity of either somatostatin- (Figure 3.15A, B)
or PP-cell (Figure 3.15C, D) population.
To elucidate by what means MEN1 knockdown reduces cellular proliferation, we
analyzed the effect of MEN1 siRNA on cell cycle regulators and the activation of the
PI3K/AKT and Wnt/β-catenin pathways. The cell cycle regulators analyzed were p18,
p21, and p27, which are cell cycle inhibitors, and cyclinD1 which promotes cell cycle
progression (Wu and Hua, 2011). In adult tissues, Menin has been shown to regulate the
expression of all four of these cell cycle regulators either directly or indirectly to reduce
proliferation (Wu and Hua, 2011). In this study, analysis of p18, p21, p27, and cyclinD1
mRNA showed no significant change with MEN1 downregulation (Appendix II:
Supplementary Figure 5A). Menin has also been shown to negatively regulate both the
PI3K/AKT and Wnt/β-catenin pathways to reduce proliferation in adults (Cao et al.,
2009; Wang et al., 2011). Here we show that with MEN1 knockdown, pAKT (indicative
of an activated pathway) and pβ-catenin (pSer675, indicative of an active Wnt pathway)
protein levels were similar between Ctrl-siRNA and MEN1-siRNA treatment groups
(Appendix II: Supplementary Figure 6).
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Figure 3.13. Effect of MEN1 siRNA on Islet-Epithelial Cell Cluster Proliferation.
Islet-epithelial cell clusters isolated from human fetal pancreata 15 to 19 wks were
transfected with either control siRNA or MEN1 siRNA for a 48 hr treatment. Cells were
harvested, paraffin-embedded, and sections were immunolabelled with an anti-KI67
antibody visualized with a Cy3 (red) conjugated secondary antibody.

Nuclei were

labelled with DAPI (blue). (A) Quantitative analysis of the total number of KI67+ cells
relative to the total amount of cells present (KI67+/DAPI, expressed as a percentage) for
control and MEN1 siRNA treatments. Data were determined by morphometric analysis
and are expressed as means ± SEM where n=4-5 for each experimental group. *p<0.05
vs. control siRNA treatment.

(B, C) Representative images denoting proliferation

(KI67+) for (B) control siRNA and (C) MEN1 siRNA treatment groups. For each set, the
top panel of images shows staining for KI67 (red), DAPI (blue), and an overlay of
images. Scale bars correspond to 25 micrometers. The bottom panels show magnified
images corresponding to the boxed section in the above image. Arrows indicate a KI67
positive cell.
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Figure 3.14. Effect of MEN1 siRNA on Endocrine Cell Proliferation and
Differentiation in Islet-Epithelial Cell Clusters.
Islet-epithelial cell clusters isolated from human fetal pancreata 15 to 19 wks were
transfected with either control siRNA or MEN1 siRNA and cultured for 48 hrs. (A-C)
Analysis of the insulin population where (D-F) describe analysis of the glucagon
population of endocrine cells. Quantitative analysis of the proliferation capacity between
control and MEN1 siRNA groups in the (A) insulin+ or (D) glucagon+ cell populations,
expressed as a percentage relative to the control treatment for each sample, where
proliferation capacity is the amount of KI67+ cells relative to a certain cell population.
Data were determined by morphometric analysis and are expressed as means ± SEM
where n=3-4 for each treatment. qRT-PCR analysis of (B) insulin and (E) glucagon gene
expression for control and MEN1 siRNA treatments. Data were normalized to 18S rRNA
and are expressed as means ± SEM where n=4-6 per experimental group. Quantitative
analysis of (C) insulin+ and (F) glucagon+ cell populations expressed as a percentage
(total insulin+ or glucagon+ cells relative to the total amount of cells present, DAPI
stained nuclei) for control and MEN1 siRNA treatments. Data were determined by
morphometric analysis and are expressed as means ± SEM where n=3-4 for each
treatment. *p<0.05 vs. control siRNA treatment.
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Figure 3.15. Effect of MEN1 siRNA on Somatostatin and Pancreatic Polypeptide
Expression.
Islet-epithelial cell clusters isolated from human fetal pancreata 15 to 19 wks were
transfected with either control siRNA or MEN1 siRNA for a 48 hr treatment. Cells were
harvested, paraffin-embedded, and sections were co-immunolabelled with an (A, B) antisomatostatin antibody or (C, D) anti-pancreatic polypeptide (PP) antibody along with an
anti-KI67 antibody which were visualized with a Cy2 (green) and Cy3 (red) conjugated
secondary antibody. Nuclei were labelled with DAPI (blue). (A, B) Representative
images for somatostatin+ and KI67+ cells for (A) control siRNA and (B) MEN1 siRNA
treatment groups. (C, D) Representative images for PP+ and KI67+ cells for (C) control
siRNA and (D) MEN1-siRNA treatment groups. For each set, the top panel of images
shows staining for somatostatin or PP (green), KI67 (red), DAPI (blue), and an overlay of
images. The bottom panels show magnified images corresponding to the boxed section
in the above image.
+

+

Scale bars correspond to 25 micrometers.
+

somatostatin or PP cells. Arrowheads indicate KI67 cells.

Arrows indicate
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3.5

Downregulation of MEN1 Effects the Expression of Transcription Factors

To explore the impact of MEN1 knockdown on islet development, the levels of various
transcription factors that are critical for human fetal islet development were analyzed
using qRT-PCR, immunofluorescence staining, and western blotting techniques
following a 48 hr MEN1 and control siRNA transfection period. Analysis of PDX1
expression following transfection showed a slight reduction in PDX1 mRNA and the
number of PDX1+ cells, however no statistical significance was found (Figure 3.16A, B).
When looking at the progenitor pool marker SOX9, there was a significant reduction in
SOX9 mRNA with MEN1 downregulation (p<0.05 vs. Ctrl-siRNA), however the SOX9
protein level was unchanged (Figure 3.16C, D). Analysis of NGN3 demonstrated stable
expression between treatment groups for both mRNA expression and the population of
NGN3+ expressing islet-epithelial cell clusters (Figure 3.16E, F). Interestingly, MEN1
knockdown did have a significant effect on NGN3 downstream transcription factors
NKX2.2 and NKX6.1 (Figure 3.17A-C). A significant decrease in NKX2.2 and NKX6.1
mRNA levels was observed with MEN1 downregulation compared with Ctrl-siRNA
treatment (Figure 3.17A, C) with no quantifiable change in the total number of NKX2.2+
cells (Figure 3.17B). Exocrine levels, assessed by the transcription factor HES1, showed
no change in HES1 mRNA levels with MEN1 downregulation (Figure 3.17D).

3.6

Downregulation of MEN1 Reduces Cell Survival Capabilities

Previous studies have demonstrated that menin functions as a tumour suppressor through
various pathways including an involvement in cell survival by promoting DNA repair and
genome stability, but also through promoting apoptotic pathways (Garcia-Higuera et al.,
2001; Gustavson et al., 1983; La et al., 2007).

Cell survival and cell death were

investigated between control and MEN1 siRNA groups using immunofluorescence
analysis of TUNEL labelling and western blot analysis of the total content of the cleaved
Caspase-3 protein (Figure 3.18). Morphological analysis of TUNEL+ cells revealed a
significant increase in apoptotic (TUNEL+) cells with MEN1 knockdown (p<0.01 vs.
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Figure 3.16. Effect of MEN1 siRNA on PDX1, SOX9, and NGN3 Expression.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either control siRNA or MEN1 siRNA for a 48 hr treatment. (A)
Analysis of PDX1 mRNA expression by qRT-PCR for control and MEN1 siRNA
treatments. (B) Quantitative analysis of the PDX1+ cell population relative to the total
amount of cells present (DAPI stained nuclei, expressed as a percentage) for control and
MEN1 siRNA groups. (C) Analysis of SOX9 mRNA expression by qRT-PCR for both
treatment groups. (D) Western blot analysis of total SOX9 protein expression (65 kDa)
normalized to calnexin expression (90 kDa) for both treatment groups, n=3 per treatment
group. (E) Analysis of NGN3 mRNA expression by qRT-PCR for both treatment groups.
(F) Quantitative analysis of the NGN3+ cell population relative to the amount of cells
present (DAPI stained nuclei, expressed as a percentage) for both treatment groups. (A,
C, E) Data were normalized to 18S rRNA where n=4-6 per experimental group. (B, F)
Data were determined by morphometric analysis where n=3-4 for each treatment. Data
were expressed as means ± SEM, *p<0.05 vs. control siRNA treatment.
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Figure 3.17. Effect of MEN1 siRNA on NKX2.2, NKX6.1, and HES1 Expression.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either control siRNA or MEN1 siRNA for a 48 hr treatment period.
qRT-PCR analysis of total (A) NKX2.2, (C) NKX6.1, or (D) HES1 gene expression for
control and MEN1 siRNA treatments. Data were normalized to 18S rRNA and are
expressed as means ± SEM where n=4-6 per experimental group. (B) Quantitative
analysis of the total NKX2.2+ cell population relative to the total amount of cells present
(DAPI stained nuclei, expressed as a percentage) for control and MEN1 siRNA
treatments. Data was determined by morphometric analysis and are expressed as means
± SEM where n=3-4 for each treatment. *p<0.05 vs. control siRNA treatment.
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Ctrl-siRNA) (Figure 3.18A). Quantification of cleaved Caspase-3 protein level in the
MEN1 siRNA group displayed an increasing trend of cleaved Caspase-3 signals where
p=0.08 (Figure 3.18B), indicating a confirmation of morphological assessment and an
increase in cell death, or a reduction in cell survival with a decrease in menin. Studies
have shown that the PI3K/AKT and Wnt/β-catenin pathways are both involved in
apoptotic regulation along with proliferation, another reason why the effect of menin
knockdown on these pathways was studied (see section 3.4) (Chen et al., 2008; Wang et
al., 2011).

3.7

Overexpression of MEN1 Promotes Proliferation and Effects Islet
Development

The effects of MEN1 overexpression in islet-epithelial cell clusters was explored using
cultured islets isolated from human fetal pancreata 15-19 wks which were transfected
with either a control pEGFP vector (Ctrl-EGFP) or a pEGFP-N2 vector with a human
full-length MEN1 cDNA insertion (N2-M1).

After a 48 hr transfection, qRT-PCR

analysis showed a significant two fold increase of MEN1 mRNA levels with N2-M1
transfection (p<0.05 vs. Ctrl-EGFP) (Figure 3.19A). Morphological analysis of isletepithelial cell cluster sections stained with an anti-menin antibody 48 hrs posttransfection also indicated a significant increase of nMenin+ cells (from approximately
75% to 90%) with N2-M1 treatment (p<0.05 vs. Ctrl-EGFP) (Figure 3.19B). Figure
3.19C, D show representative images illustrating menin overexpression within isletepithelial cell clusters.
The functional role of menin in regulating proliferation during human fetal pancreatic
development was investigated with increasing menin expression (N2-M1 transfection).
Quantification of the proliferative cell population displayed a significant increase in
KI67+ cells with menin overexpression (p<0.05 vs. Ctrl-EGFP) (Figure 3.20). These
results correspond with and confirm those found in Figure 3.13 with a knockdown of
menin expression.

Our next step was to determine if this increase in proliferation

affected a specific endocrine population. Examination of insulin (Figure 3.21A) and
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Figure 3.18. Effect of MEN1 siRNA on Cell Death in Islet-Epithelial Cell Clusters.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either control siRNA or MEN1 siRNA for a 48 hr treatment period. (A)
Quantitative analysis of the total amount of TUNEL+ cells relative to the total amount of
cells present (DAPI stained nuclei, expressed as a percentage) for both control and MEN1
siRNA treatment groups. Data were determined by morphometric analysis. (B) Western
blot analysis of cleaved Caspase-3 (cCaspase-3) protein expression (17, 19 kDa) relative
to total Caspase-3 (tCaspase-3) protein expression (35 kDa) for both treatment groups,
normalized to control. Representative images of TUNEL labelling for (C) control or (D)
MEN1 siRNA treatment groups. Cells were harvested, paraffin-embedded, sections were
TUNEL labelled (green) as in Section 2.2, and the nuclei were labelled with DAPI (blue).
For each set, the top panel of images shows staining for TUNEL (green), DAPI (blue),
and an overlay of images. Scale bars correspond to 25 micrometers. The bottom panels
show magnified images corresponding to the boxed section in the above image. Arrows
indicate a TUNEL positive cell. Data are expressed as means ± SEM. n=3. **p<0.01
vs. control siRNA treatment.
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Figure 3.19. Effect of MEN1 Overexpression on MEN1 mRNA and nMenin in
Islet-Epithelial Cell Clusters.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either a control (Ctrl-EGFP) or a MEN1 (N2-M1) vector and cultured for
48 hrs. (A) qRT-PCR analysis of total MEN1 mRNA levels for control and N2-M1
treatments. Data were normalized to 18S rRNA and are expressed as means ± SEM
where n=6 per experimental group. (B) Quantitative analysis of the total number of
nMenin+ cells relative to the total amount of cells present (nMenin+/DAPI, expressed as a
percentage) of both control and N2-M1 groups. Data are expressed as means ± SEM
where n=3-4 for each experimental group. *p<0.05 vs. Ctrl-EGFP treatment. (C, D)
Representative images of islet-epithelial cell clusters for (C) control or (D) N2-M1
treatment groups.

Cells were harvested, paraffin-embedded, and sections were

immunolabelled with an anti-menin antibody visualized with a Cy2 (green) conjugated
secondary antibody. Nuclei were labelled with DAPI (blue). For each set, the top panel
of images shows staining for menin (green), DAPI (blue), and an overlay of images.
Scale bars correspond to 25 micrometers. The bottom panels show magnified images
corresponding to the boxed section in the above image. Arrows indicate a nuclear menin
positive cell.
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Figure 3.20. Effect of MEN1 Overexpression on Islet-Epithelial Cell Cluster
Proliferation.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either a control (Ctrl-EGFP) or a MEN1 (N2-M1) vector and cultured for
48 hrs. Cells were harvested, paraffin-embedded, and sections were immunolabelled
with an anti-KI67 antibody visualized with a Cy3 (red) conjugated secondary antibody.
Nuclei were labelled with DAPI (blue). (A) Quantitative analysis of the total number of
KI67+ cells relative to the total amount of cells present (KI67+/DAPI, expressed as a
percentage) for control and N2-M1 treatments. Data are expressed as means ± SEM
where n=3 for each experimental group. *p<0.05 vs. control-EGFP treatment. (B, C)
Representative images denoting proliferation (KI67+) for (B) control and (C) N2-M1
treatment groups. For each set, the top panel of images shows staining for KI67 (red),
DAPI (blue), and an overlay of images. Scale bars correspond to 25 micrometers. The
bottom panels show magnified images corresponding to the boxed section in the above
image. Arrows indicate a KI67 positive cell.
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glucagon (Figure 3.22A) mRNA with qRT-PCR showed no changes in the N2-M1
treatment group when compared to the control group. Immunofluorescence staining
techniques were employed for insulin (Figure 3.21B, C), glucagon (Figure 3.22B, C),
somatostatin (Figure 3.23A, B), and pancreatic polypeptide (Figure 3.23C, D)
expressing endocrine cells, all of which exhibited similar populations with menin
overexpression compared to the control groups.
To elucidate by what means MEN1 overexpression increases cellular proliferation, we
analyzed the effect of N2-M1 transfection on cell cycle regulators similar to section 3.4.
In this study, analysis of p18, p21, and p27 mRNA showed no significant change with
MEN1 overexpression (Supplementary Figure 5B).
To further explore a function of menin within islet cell development and differentiation,
various transcription factors which are critical for endocrine development were chosen
and analyzed by qRT-PCR using PDX1, SOX9, NGN3, NKX2.2, and NKX6.1 probes
(Figure 3.24). Analysis of these results indicated consistent mRNA levels for PDX1 and
NGN3. Examination of SOX9 revealed a significant 4.5 fold increase in SOX9 mRNA
expression with overexpression of menin. NKX2.2 analysis displayed an increasing trend
with N2-M1 transfection where p=0.0527 and NKX6.1 mRNA expression also displayed
an increasing trend but was highly variable.

3.8

Menin Overexpression Improves Cell Survival Capabilities

As previously mentioned, menin is involved in cell survival in many ways, two of which
include roles in DNA repair and apoptosis. This functionality of menin was studied in
islet-epithelial cells transfected with either a control-EGFP vector or a menin
overexpression vector (N2-M1). Treated cells were exposed to a TUNEL labelling assay
which displayed a significant reduction in the number of apoptotic labelled cells with N2M1 treatment (p<0.01 vs. Ctrl-EGFP) (Figure 3.25A). This result was further verified by
cleaved Caspase-3 analysis where immunofluorescence examination indicated a
significant reduction in apoptosis (cleaved Caspase-3+ cells) with N2-M1 transfection
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(p<0.05 vs. Ctrl-EGFP) (Figure 3.25B), validating the TUNEL results and demonstrating
an improved cell survival with menin overexpression.
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Figure 3.21. Effect of MEN1 Overexpression on Insulin Expression.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either a control (Ctrl-EGFP) or a MEN1 (N2-M1) vector and cultured for
48 hrs. (A) qRT-PCR analysis of total insulin mRNA levels for control and N2-M1
treatments. Data were normalized to 18S rRNA and are expressed as means ± SEM
where n=6 per experimental group. (B, C) Representative images of islet-epithelial cell
clusters for (B) control or (C) N2-M1 treatment groups. Cells were harvested, paraffinembedded, sectioned, and immunolabelled with an anti-insulin antibody visualized with a
Cy3 (red) conjugated secondary antibody. Nuclei were labelled with DAPI (blue). For
each set, the top panel of images shows staining for insulin (red), DAPI (blue), and an
overlay of images. The bottom panels show magnified images corresponding to the
boxed section in the above image. Scale bars correspond to 25 micrometers. Arrows
indicate an insulin positive cell.
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Figure 3.22. Effect of MEN1 Overexpression on Glucagon Expression.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either a control (Ctrl-EGFP) or a MEN1 (N2-M1) vector and cultured for
48 hrs. (A) qRT-PCR analysis of total glucagon mRNA levels for control and N2-M1
treatments. Data were normalized to 18S rRNA and are expressed as means ± SEM
where n=6 per experimental group. (B, C) Representative images of islet-epithelial cell
clusters for (B) control or (C) N2-M1 treatment groups. Cells were harvested, paraffinembedded, sectioned, and immunolabelled with an anti-glucagon antibody visualized
with a Cy3 (red) conjugated secondary antibody. Nuclei were labelled with DAPI (blue).
For each set, the top panel of images shows staining for glucagon (red), DAPI (blue), and
an overlay of images. The bottom panels show magnified images corresponding to the
boxed section in the above image. Scale bars correspond to 25 micrometers. Arrows
indicate a glucagon positive cell.
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Figure 3.23. Effect of MEN1 Overexpression on Somatostatin and Pancreatic
Polypeptide Expression.
Islet-epithelial cell clusters isolated from human fetal pancreata 15 to 19 wks were
transfected with either a control (Ctrl-EGFP) or a MEN1 (N2-M1) vector for a 48 hr
treatment. Cells were harvested, paraffin-embedded, and sections were immunolabelled
with an (A, B) anti-somatostatin antibody or (C, D) anti-pancreatic polypeptide (PP)
antibody which were visualized with a Cy2 (red) conjugated secondary antibody. Nuclei
were labelled with DAPI (blue). (A, B) Representative images of somatostatin+ cells for
(A) control and (B) N2-M1 treatment groups. (C, D) Representative images of PP+ cells
for (C) control and (D) N2-M1 treatment groups. For each set, the top panel of images
shows staining for somatostatin or PP (red), DAPI (blue), and an overlay of images. The
bottom panels show magnified images corresponding to the boxed section in the above
image. Scale bars correspond to 25 micrometers. Arrows indicate a somatostatin+ or PP+
cell.
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Figure 3.24. Effect of MEN1 Overexpression on Transcription Factors Essential
for Endocrine Differentiation.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either a control (Ctrl-EGFP) or a MEN1 (N2-M1) vector and cultured for
48 hrs. For control (transparent bars) and N2-M1 (black bars) treatment groups, qRTPCR analysis for PDX1, SOX9, NGN3, NKX2.2, and NKX6.1 mRNA.

Data were

normalized to 18S rRNA and are expressed as means ± SEM where n=4-6 per
experimental group, *p<0.05 vs. Ctrl-EGFP.
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Figure 3.25. Effect of MEN1 Overexpression on Cell Death in Islet-Epithelial Cell
Clusters.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either a control (Ctrl-EGFP) or a MEN1 (N2-M1) vector and cultured for
48 hrs. Cells were harvested, paraffin-embedded, and sections were immunolabelled
with an anti-cleaved Caspase-3 antibody visualized with a Cy2 (green) conjugated
secondary antibody or sections were TUNEL labelled (green). Nuclei were labelled with
DAPI (blue). Quantitative analysis of the total number of (A) TUNEL+ cells and (B)
cleaved Caspase-3 (cCaspase-3)+ cells relative to the total amount of cells present
(TUNEL or cCaspase-3/DAPI, expressed as a percentage) for control and N2-M1
treatments. Data are expressed as means ± SEM. n=3. *p<0.05, **p<0.01 vs. Ctrl-EGFP
treatment. Representative images denoting TUNEL labelling for (C) control and (D) N2M1 treatment groups. For each set, the top panel of images shows staining for TUNEL
(green), DAPI (blue), and an overlay of images.

Scale bars correspond to 25

micrometers. The bottom panels show magnified images corresponding to the boxed
section in the above image. Arrows indicate a TUNEL positive cell.
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Chapter 4 – Discussion
The objective of this study was to examine the expression pattern and functional roles of
menin during human fetal islet development through its association and interaction with
other necessary transcription factors. Previous studies have shown Menin to be essential
during murine pancreatic development, however little information is known regarding the
expression of menin or its function during human fetal pancreatic development. From
our knowledge within the murine species, I have hypothesized that menin is required for
islet differentiation by regulating islet progenitor proliferation and the expression of
NGN3 and other essential pancreatic transcription factors in the developing human
pancreas. The expression pattern of menin and its function was elucidated by examining
five questions using ex vivo and in vitro experimental techniques (see section 1.4 for a
complete list of these 5 questions as described below). Initially, ex vivo techniques were
employed using the whole human fetal pancreas revealing a consistent menin expression
pattern within various cell types, and its co-localization with multiple transcription
factors that are critical for pancreatic development. The developmental time period
analyzed was from 8-21 wks of fetal age, a period characterized by major morphological
changes of pancreatic and islet architecture (Lyttle et al., 2008). In vivo siRNA and
overexpression studies were utilized to explore the function of menin, demonstrating
roles for menin in maintenance of proliferation, transcription factor expression, and cell
survival during human pancreatic development.

4.1

What is the Spatial and Temporal Expression Pattern of Menin Throughout
Human Pancreatic Development?

By understanding the spatio-temporal distribution pattern of menin at differing stages in
the development of the human pancreas, this allowed us to further deduce the role menin
may be playing during islet cell development. To address the temporal expression of the
MEN1 gene, this study employed both mRNA and protein analysis techniques using
pancreata collected during the 1st and 2nd trimester of pregnancy. Previously in our
laboratory, microarray investigation of 8-21 wk human fetal pancreata revealed that
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MEN1 is highly expressed relative to adult pancreatic islets and qRT-PCR experimental
results have shown that MEN1 is expressed consistently during human pancreatic
development.

Quantitative analysis of protein collected from whole fetal pancreata

during this study showed that menin was indeed expressed at all time points from the 1st
through the 2nd trimester at a relatively consistent amount. Expression studies of Menin
within the developing mouse have reported that Menin expression begins at e7 (prior to
pancreatic bud formation) within the majority of tissues and is expressed in the pancreas
at e11.5 through e18.5 and into adulthood (Chandrasekharappa et al., 1997; Fontaniere et
al., 2008; Stewart et al., 1998). This period from e11.5-e18.5 in the mouse is similar to
the developmental window in our study as it describes a time from which the ductal tree
is forming, with pancreatic buds predominately consisting of undifferentiated ductal
epithelium and few single endocrine cells present, through to an almost fully formed
pancreas with endocrine cells condensed into islet cell clusters (Habener et al., 2005).
Therefore our temporal expression pattern of menin corresponds with the presence of
menin described by Fontaniere and colleagues in 2008 from e11.5-e18.5. However, they
did not perform quantification studies as we have provided in this study. To perform
menin expression analysis we used mRNA and total protein collected from whole fetal
human pancreata consisting of both cytoplasmic and nuclear fractions such that our
results here were unable to reflect any such changes in the sub-cellular localization of
menin throughout pancreatic development. To determine menin sub-cellular fluctuations,
nuclear/cytoplasmic extraction techniques are needed. Nuclear menin expression was
however present at all developmental stages studied because all localization studies and
islet cell quantifications were performed using immunofluorescence techniques which
focused on nMenin localization. This is because the nuclear fraction represents the active
form of menin (Guru et al., 1998).
To determine the spatial distribution of menin expression throughout development,
immunofluorescence co-localization was performed from 8-21 wks of fetal age. Results
revealed expression within endocrine cells (insulin+, glucagon+, somatostatin+ cells),
ductal cells (CK19+), and in the exocrine (amylase+) compartment at all time points
studied.

Morphometric analysis focused on quantifying the localization of menin

throughout development within alpha, beta, and ductal cells. Ductal cells were analyzed
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as they are the location of pancreatic progenitors, endocrine progenitors, and fully
differentiated endocrine cells (before they migrate out into surrounding tissue) (Bouwens
et al., 1997). Insulin+ and glucagon+ cells both showed a consistent high level of menin
expression throughout development, and menin co-localization was significantly reduced
within ductal cells during 14-16 wks compared to 8-12 wks. This may suggest that there
is a change of requirement or function for menin at 14-16 wks, a period of increased
differentiation and reduced proliferation. At 14-16 wks all epithelial cells, including
endocrine cells, are CK19+, and since there is no change in menin localization within
endocrine cells, this ductal localization reduction may not be due to endocrine
differentiation. The co-localization studies of menin with various transcription factors as
well as functional knockdown and overexpression studies (which are discussed in the
following sections) gives us more insight into the role of menin and its presence during
endocrine differentiation. Cytoplasmic assessment as well as menin protein abundance
within each cellular compartment was not taken into consideration in the current study.
Future analysis such as cell sorting in combination with nuclear/cytoplasmic extraction
techniques will allow for precise analysis of menin protein abundance and distribution
within purified cell populations, and also within separate cellular compartments. Overall,
these localization results show the expression of menin in all compartments of the
pancreas during development and correspond with various studies during murine
pancreatic development (at e16, e18) and within the fully developed adult pancreas of
both humans and rodents (Cavallari et al., 2009; Fontaniere et al., 2008; Karges et al.,
1999; Thakker, 1998). This cell type-independent menin expression leads us to postulate
that menin may be involved in a global cellular function or pathway which is common to
most cell types in the pancreas.
Our results outline the spatio-temporal distribution pattern of menin within the
developmental window of 8-21 wks of fetal age. Due to ethical guidelines we were
unable to confirm the expression of menin and its stability both within the pancreas as a
whole and within pancreatic compartments prior to 8 wks during bud and initial
endocrine progenitor development and following 21 wks during maturation up until birth.
Studies using human stem cells differentiated into pancreatic endocrine cell lineages
could give us more insight into the involvement of menin prior to 8 wks in the pancreas,
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similar to the study performed by Zhang and colleagues using mouse embryonic stem
cells (Zhang et al., 2011). Cell cultures could also be employed for studies post 21 wks,
however this may prove difficult as we demonstrate the involvement of menin in
apoptotic regulation (see sections 4.4 and 4.5).

4.2

What Developmental Transcription Factors are Co-localized with Menin in
the Developing Human Fetal Pancreas?

To further elucidate at which stage of endocrine differentiation nuclear menin may be
present and performing its function, we studied the co-expression of menin with various
transcription factors that are critical throughout pancreatic development. Our results
show co-localization with all transcription factors studied from 8-21 wks; PDX1, SOX9,
ISL1, NGN3, NKX2.2, and NKX6.1. This suggests that menin is found within cells at
each stage of the endocrine differentiation process, from pancreatic progenitors at 8 wks
until the fully differentiated mature islets at 21 wks. During the period from 14-16 wks
we observed an increase in nMenin/PDX1+ co-localization within PDX1+ cells. At this
time point, PDX1+ cells can be found within the ductal cell population as well as within
newly-formed insulin+ cells, such that PDX1 regulates insulin gene expression in this
period where there is a significant increase in endocrine differentiation and pancreatic
insulin content and secretion (Lyttle et al., 2008). Since PDX1 expression is consistent
throughout development, the increase in nMenin within the 14-16 wk time point may not
be involved in regulating PDX1, but may work in tandem with PDX1 and be involved in
regulating endocrine initiating pathways within PDX1+ cells at this time point. Previous
studies have shown that Menin is present throughout the pancreatic epithelium from
e11.5-e18.5 (a period similar to our time point 8-21 wks), specifically in Insulin,
Glucagon, and ductal cells, suggesting that any transcription factor which localizes to
these compartments, for example NGN3, must also express Menin. Also, studies using
Pdx1-directed Cre knockdown of Menin confirm a co-localization, however most
research focuses on the levels of transcription factor expression post Menin knockdown,
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and thus the co-localization of menin with transcription factors have not been specifically
addressed during fetal development (Shen et al., 2009).
Although immunofluorescence co-staining allows us to analyze the sub-cellular
localization of each transcription factor with menin, our results focused on nuclear colocalization of menin with various nuclear transcription factors.

Most transcription

factors however (ie. NGN3), are also cytoplasmic (similar to menin) and so our results
could not take into account a possible change in sub-cellular localization throughout
development (Lejonklou et al., 2009). Some transcription factors (ie. PDX1 and SOX9)
are also expressed in multiple cellular populations such that some populations express a
higher or lower expression level of that specific transcription factor (Lyttle et al., 2008).
For example SOX9 is highly expressed in pancreatic progenitors and its expression
decreases as endocrine cells mature such that during our analysis there were SOX9 highand SOX9 low-expressing cells (McDonald et al., 2012).

Immunofluorescence

techniques were held stable with consistent analysis parameters to account for any
discrepancy in sub-cellular localization or alterations in expression intensity, however
techniques involving cell sorting and nuclear/cytoplasmic extraction could provide more
accurate and detailed co-localization and quantification results.

4.3

What is the Relationship Between Proliferating Cells and Menin+ Cells in the
Developing Human Fetal Pancreas?

The relationship of menin and proliferating (KI67+) cells was initially assessed
throughout development using double-immunofluorescence staining of ex vivo pancreatic
sections from 8-21 wks of fetal age. Our results showed that the proliferation capacity of
nMenin+ cells decreased as development progressed. This result was not unexpected as
Bouwens et al., 1997, noted an overall pancreatic decrease in KI67+ labelling index from
8-41 wks. Specifically, they demonstrated a decrease in proliferation of ductal, insulin,
glucagon, and synaptophysin (a non-specific endocrine marker) positive cells (Bouwens
et al., 1997). We also showed that approximately 80% of all proliferating cells in the
pancreas also express nMenin and that this is significantly reduced at 18-21 wks. This

111
data suggests that menin may not be functioning as a tumour suppressor from 8-16 wks
of fetal age since proliferation of pancreatic cells is optimal early in development
(Bouwens et al., 1997). A reduction in co-localization at 18-21 wks may indicate that the
role of menin in proliferation may change between the 14-16 wks and 18-21 wk time
points as islets develop the adult-like phenotype. In the adult pancreas, menin functions
as a tumour suppressor such that a knockdown of menin produces endocrine and ductal
cell tumours, as well as an increase in beta-cell mass during compensatory situations such
as obesity and pregnancy (Cavallari et al., 2009; Chandrasekharappa et al., 1997; Karnik
et al., 2007). Therefore as beta-cells become adult-like and their proliferation decreases,
menin may be involved in repressing proliferation after the phase of endocrine
differentiation in mature islets (Bouwens et al., 1997; Lyttle et al., 2008). A difference of
function for menin between fetal development and adulthood has been suggested for
osteoblast differentiation, as well as during development of the heart, CNS, liver, and
pancreas (Bertolino et al., 2003a; Fontaniere et al., 2008; Sowa et al., 2004). A study
involving cells, possibly cell cultures, prior to 8 wks and post 21 wks could confirm this
hypothesis, as ethical reasons halted us from obtaining primary cells at these time points.
Also, our results were only able to indicate the presence of menin in the overall
proliferation pool during development. Cell sorting techniques isolating certain cell
populations

(i.e.

GLUT1

surface

marker

for

beta-cells)

and

subsequent

immunofluorescence staining could indicate if there may be any change in the expression
of menin within proliferating cells of a certain cell population throughout development,
as well as detecting any change between cell populations.

4.4

Does Downregulation of MEN1 in Islet-Epithelial Cell Clusters Affect
Endocrine Cell Proliferation and Differentiation?

To analyze the function of menin during endocrine differentiation, MEN1 knockdown
was performed using MEN1 siRNA transfection in islet-epithelial cell clusters 15-19 wks
of fetal age. With time-dependent trials, we determined that a 48 hr siRNA incubation
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was the optimal time for MEN1 and nMenin knockdown, therefore subsequent functional
analysis trials were performed at this time point.
Since mutation in the MEN1 gene results in the multiple endocrine neoplasia type 1
disease, menin has been characterized as a tumour suppressor where its main function is
to suppress proliferation in adult endocrine tissues. Using a knockdown strategy we
sought to determine if menin still functions as a tumour suppressor during endocrine
differentiation in the human fetal pancreas. Our ex vivo results of menin co-localization
within KI67+ cells (as discussed in section 4.3) indicate that menin may not function to
suppress proliferation during endocrine differentiation (14-16 wks) and that this function
may change as endocrine cells mature.

MEN1-siRNA-mediated knockdown results

revealed a significant decrease in proliferation levels of islet-epithelial cell clusters at 1519 wks (compared to control siRNA). These results coincide with our ex vivo results but
are in sharp contrast to the function of menin within the adult pancreas. This change in
function between development and adulthood would not be out of the ordinary as other
proteins such as tumour suppressor, Rb, have been shown to be required during normal
retinal development (Fontaniere et al., 2008). Our next step was to determine which
endocrine cell populations were experiencing a reduction in proliferation after menin
silencing and how this affected their overall total cell population. Our results indicated
that menin had no effect on the proliferation capacity of insulin+ cells, the expression of
insulin mRNA, or the total number of insulin+ cells. Our results also indicated that a
reduction in menin resulted in a significant decline in the proliferation capacity of
glucagon+ cells. Data published by Lyttle et al in 2008 demonstrated that alpha-cell (not
beta-cell) proliferation was significantly increased during the 2nd trimester. This may
explain why menin affected glucagon-cell proliferation only, the specificity to alpha-cells
is because the increase in beta-cell mass at this stage of development is mostly due to
differentiation from endocrine precursors. Although our results showed a reduction in
alpha-cell proliferation, there were no changes in glucagon mRNA expression or the
number of glucagon+ cells. It may be possible that a reduction in proliferation results in
an increase in differentiation (from pancreatic or endocrine precursor cells) as a
compensatory mechanism to maintain normal alpha-cell numbers. Menin may therefore
be functioning to regulate the transition from proliferation to differentiation. Many
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studies have implicated menin-interacting partners and menin-regulatory proteins in the
regulation of the proliferation to differentiation transition in a variety of tissues.
Examples of these proteins are p27, CDK 4 and 6, JunD, members of Wnt/β-catenin,
ERK1/2, and NFκB pathways (via RunX2) (Andreu-Perez et al., 2011; Hara et al., 2011;
Kaji et al., 2009; Lim and Kaldis, 2012; Naito et al., 2005; Wei et al., 2011). Menin may
thus be involved in regulating alpha-cell proliferation and differentiation exclusively.
To determine the mechanism by which menin represses proliferation, we analyzed the
expression of cell-cycle regulators, p18, p21, and p27, as well as members of both the
Wnt/β-catenin and the PI3K/AKT pathways. None of these were altered with MEN1
knockdown, therefore menin must be regulating proliferation through alternative
pathways. A microarray of MEN1 knockdown cells with various essential pancreatic
differentiation probes could be an alternative to determine multiple gene expression
changes associated with a reduction of menin. Although immunofluorescence staining
was also performed for somatostatin+ and PP+ endocrine cells, quantification of
proliferation capacity and the total cell population count was not analyzed. Due to the
low percentage of somatostatin- and PP-cells within the pancreas itself, the number of
these cells within islet-cell clusters was minimal, and so a representative quantification
would not be possible. However, upon observation there were no obvious changes in
somatostatin- or PP-cell populations with MEN1 knockdown.

One could combine

samples such that one would have a representative number of somatostatin- and PP-cells
to overcome this barrier, however due to restrictions on sample availability we were
unable to do this therefore no results were obtained and we decided to focus on the alphaand beta-cell differentiation process from progenitor cells.
To confirm if menin is involved in differentiation and to determine where menin may be
functioning within the transcription factor network, we analyzed factors critical in
progenitor pool maintenance and endocrine differentiation. There was a slight decrease
but no significant change in the levels of PDX1 mRNA or the PDX1+ cell population.
This suggests that menin may act downstream of PDX1. Interestingly, SOX9 mRNA
level was significantly decreased with MEN1 knockdown, but the overall level of SOX9
protein expression was unaltered. It is possible that a reduction in mRNA has not yet
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affected the protein level, and a longer period of siRNA treatment might be necessary for
SOX9 mRNA reduction and for reduction of overall protein expression. NGN3, the
major regulator of endocrine differentiation for all endocrine cell lines, was analyzed and
there may be a slight increase but no significant change in NGN3 mRNA or the number
of NGN3+ expressing cells with menin knockdown (Lyttle et al., 2008).

Two

downstream genes of NGN3 were significantly reduced with MEN1 knockdown. These
were NKX2.2 and NKX6.1, genes critical for alpha- and beta-cell differentiation (Lyttle et
al., 2008). HES1, a gene expressed during exocrine pancreas development was also
analyzed showing no alteration in mRNA expression. This was expected as previous
research in cultured Men1 null cells showed that menin, although present in exocrine
cells, was not involved in exocrine pancreas development (Fontaniere et al., 2008).
Overall, our analyses of critical transcription factors reveal that menin promotes SOX9,
NKX2.2, and NKX6.1 expression, but does not affect PDX1, NGN3, and HES1
expression. These results suggest that menin is involved in preserving the progenitor
pool and promoting normal expression of endocrine differentiation markers.
Another function of menin during adulthood is regulation of apoptosis. Within adult
tissues menin has been shown to regulate apoptosis in a variety of ways through
promoting DNA repair and chromosome stability pathways, but also by promoting cell
death through the Caspase-8 cascade (Gallo et al., 2010; La et al., 2007). In human fetal
development we have shown that a knockdown of menin increases overall cell death and
the cleaved Caspase-3 cascade. These results indicate that during development menin is
functioning to suppress apoptosis. The method through which menin is promoting cell
survival in fetal tissues has yet to be determined, but we can conclude that it may not be
functioning to promote the caspase cascade as in adult pancreatic tissues. These results
correspond with Men1 null pancreata which show an increase in apoptosis with menin
knockdown at e12.5, suggesting that menin promotes cell survival of endocrine
progenitors (Fontaniere et al., 2008).
Our results correspond with some studies, though there are also some differences. Men1
global knockout mice die in utero suggesting a requirement of menin in differentiation,
specifically the differentiation of early pancreatic endocrine cells. Cultured Men1 null
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pancreatic cells also suggest that menin is required during the major wave of endocrine
differentiation, and that this function may be through NGN3 regulation. We did not see
an overall decrease in insulin or glucagon cells as the null mouse pancreata indicates, but
our results confirm that menin is required for normal endocrine differentiation. Our
MEN1 knockdown cultures did not display any significant alterations in NGN3 mRNA or
the number of NGN3 producing cells, but one cannot dismiss the fact that there may have
been

an

overall

change

in

NGN3

protein

expression

within

each

cell.

Nuclear/cytoplasmic extraction techniques with subsequent western blotting would be
able to quantify and determine the nuclear expression of NGN3. We did see aberrant
transcription factor expression with menin knockdown and the precise effect of this has
yet to be determined. There may be a reduction in other endocrine cells that we are not
able to quantify due to sample quantity limitations or an alteration in the functionality of
differentiated endocrine cells. For example, Nkx2.2 knockout mice display aberrant
endocrine differentiation with an increasing production of Ghrelin-producing endocrine
cells to compensate for the lack of beta-cells (Prado et al., 2004). As well, studies show
lack of Nkx2.2 expression in mature endocrine cells results in reduced insulin expression,
pancreatic insulin content, and insulin secretion (Doyle and Sussel, 2007). Our results do
not show a change in insulin expression, however should these cells be allowed to
propagate further with a reduction in menin, one might observe this result. Further
propagation could be achieved if menin did not have such an effect on apoptosis and
would also require sustained menin reduction, obtained by using shRNA constructs
instead of siRNA–mediated transient knockdown. Also, no change in insulin mRNA or
the number of insulin+ cells does not necessarily mean there may not be a change in the
insulin content and density of the insulin granules in the cells. One could quantify this by
determining the total insulin intensity in sections from immunofluorescence staining and
comparing knockdown and control treatment groups.

Differentiated Men1 null

embryonic stem cells into EBs did show some additional similarities to our results. This
EB study, by Zhang and colleagues in 2011, indicated that menin knockdown may
preferentially initiate differentiation at an earlier time point along the endodermal
pathway and reduce Nkx2.2 expression. Our results showing reduction in glucagon
proliferation, with a normal quantification of the glucagon+ cell population in MEN1-
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siRNA-treated cells, suggest that similar to null EBs, menin promotes proliferation and
represses differentiation (Zhang et al., 2011). This hypothesis came from the fact that
when proliferation is reduced in stem cells, they transition to differentiation.

For

example, this transition is seen within neural stem cells with CDK2 and CDK4 knocked
out but not within differentiated MEFs (mouse embryonic fibroblasts) (Lim and Kaldis,
2012).

Our results with partially-differentiated pancreatic cells may not show this

effective transition to differentiation with a reduction in proliferation. Our transcription
factor study suggests that menin may be promoting differentiation by promoting the
expression of SOX9, NKX2.2, and NKX6.1.

Thus, the involvement of menin in

+

promoting glucagon cell proliferation may be a separate function from differentiation
within the partially-differentiated pancreatic epithelium at 15-19 wks.
The effect of SOX9 repression could account for some of the alterations that we see in
our MEN1 knockdown cell cultures. Pancreatic specific Sox9-inactivated mouse embryos
showed a reduction in progenitor pool proliferation and cell survival; a phenomenon seen
within our results indicating that the reduction in proliferation and cell survival may be
within the progenitor pool (Seymour et al., 2007). Subsequent studies could determine
the proliferation capacity of SOX9+ cells with menin knockdown and which cell type are
representative of the increase in cell death. SOX9 has been shown in the murine and
human fetal pancreas to be required in proliferation, and during endocrine neogensis
SOX9 promotes differentiation by binding to and regulating the NGN3 promoter and
regulation of downstream transcription factors (ie. NKX6.1) (McDonald et al., 2012;
Seymour et al., 2008).

Within our results the knockdown in SOX9 may also be

responsible for the reduction in differentiation markers NKX2.2 and NKX6.1, although we
did not see a reduction in NGN3 mRNA or the number of NGN3+ cells. However as
stated previously, the protein expression within each cell may be altered, or the NGN3
promoter may be regulated by other proteins such that this SOX9-induced repression is
masked by some other compensatory mechanism. SOX9 is also involved in a variety of
other processes during human fetal development, such that haploinsufficiency of SOX9
(beginning at 14 weeks of gestation) results in campomelic dysplasia. Patients with this
disorder at birth display less densely-packed epithelial cells within the mesenchymal
stroma along with islets that are less clearly formed with variable expression of hormone
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and beta-cell markers. We did not see an observable difference in islet packing density
(with DAPI florescence staining), but we did see variable beta-cell markers with MEN1
knockdown. Overall, SOX9 is a key player in all of our results showing changes in
proliferation, cell survival, and the transcription factor cascade.
A knockdown of Nkx6.1 in murine pancreata results in reduced beta-cell differentiation
with normal development of other endocrine cell fates, and no difference in exocrine
development such that Nkx6.1 may function downstream of NKX2.2 to affect only betacells (Sander et al., 2000). In the human fetal pancreas NKX6.1 is highly expressed in
beta-cells only, with only a very low expression density within ductal cells, suggesting
that NKX6.1 is required in beta-cell differentiation exclusively (Lyttle et al., 2008). We
did see a reduction in NKX6.1 during menin knockdown but no effects were seen on betacell quantification. Another function of NKX6.1 includes its involvement in suppressing
the alpha- to beta-cell transition as well as islet proliferation and glucose-stimulated
insulin secretion in the mature adult pancreas. Further studies could be performed to see
how MEN1 knockdown affects other aspects of NKX6.1 function, such as a possible
alpha- to beta-cell transition within development and an effect on insulin secretion as
beta-cells become mature and fully differentiated.
The presence of MEN1 disease characteristics and the lack of developmental defect in
Menin heterozygous mice and beta-cell specific Menin knockout mice may be due to a
threshold effect of Menin expression. Within our results we obtained about a 40-50%
knockdown of menin compared to control siRNA treated islet-epithelial cell clusters and
so we observed a developmental effect and requirement for menin in human fetal
pancreatic development. Heterozygous Men1 mice displayed normal menin expression
within islets and it was hypothesized that the reduction in menin expression by 50% at 9
months of age was the cause of increasing islet hyperplasia, a resulting menin dosage
effect (Crabtree et al., 2001). Beta-cell-specific menin knockdown mice were the result
of Insulin- and Pdx1-directed Cre recombination and presented with MEN1 disease
characteristics at 2 and 3 months respectively with no change in pancreatic development
(Bertolino et al., 2003b; Shen et al., 2009). In the Insulin-directed Cre model, menin was
excised beginning at e11 but no data demonstrated menin protein depletion until
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hyperplastic islets were analyzed at 2 m. Only 3 out of 11 beta-cell knockout mice
displayed menin depletion and hyperplasia at 2 months of age (Bertolino et al., 2003b).
This indicates that there must be a dosage response to menin expression or that there may
have been Cre-mediated gene disruptions among targeted cells during embryonic
development for both Insulin- and Pdx1-directed Cre recombination (Fontaniere et al.,
2008). Together, our results confirm a dose dependence threshold effect for the effect of
menin on pancreatic development.
In summary, menin knockdown results indicate that menin is required in the developing
human fetal pancreas where it functions to promote pancreatic proliferation,
differentiation of endocrine cells (or promote alterations in the cascade of endocrine
differentiation), and promotes cell survival. Menin would thus exhibit its function within
the pancreatic progenitor pool (SOX9+ cells) and also within endocrine progenitors
downstream of NGN3 (but upstream of NKX2.2 and NKX6.1). This is a different
function of menin compared to its anti-tumourigenic role in the fully development
endocrine pancreas. The requirement of menin has been implicated in a number of
murine developmental studies (not just pancreatic development) and we believe this is the
first time menin has been shown to be a requirement for normal human fetal endocrine
development.

4.5

Does Overexpression of MEN1 in Islet-Epithelial Cell Clusters Affect
Endocrine Cell Proliferation and Differentiation?

To confirm our results found with MEN1 knockdown, we took a complementary
approach in which we overexpressed MEN1 within islet-epithelial cell clusters of the
same time point, 15-19 wks, derived from isolated human fetal pancreata. Experimental
analysis of MEN1 overexpression (termed N2-M1 treatment) on the proliferation capacity
of islet-cell clusters revealed that menin promoted islet proliferation.

qRT-PCR

techniques showed that there was no change in insulin or glucagon expression, and upon
observation only there were no apparent changes in endocrine (insulin, glucagon,
somatostatin, or PP) cell population levels.

However a more in-depth study and
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quantification of each cell population level, as well as their proliferation capacity, could
be performed in future studies. Cell sorting techniques as well as nuclear/cytoplasmic
extractions could give a more precise measurement of their proliferation capacity, gene
and hormone expression levels. The mRNA levels of cell cycle regulators, p18, p21, and
p27, showed no change with N2-M1 treatment; thus along with the MEN1 knockdown
studies, one can conclude that menin may not elicit its pancreatic functions by regulating
these cell cycle genes. Analysis of transcription factors which are critical for endocrine
differentiation revealed similar implications for menin as in our MEN1 knockdown
experiments. There was no change in the levels of PDX1 or NGN3 mRNA, but there was
a significant increase in SOX9 mRNA, an increase in NKX2.2 (p=0.527), and an
increasing trend of NKX6.1, although this marker was highly variable. These results
indicate an inherent requirement for menin during development for normal endocrine
differentiation. Overexpression of MEN1 also showed an improvement in cell survival
capabilities of islet-epithelial cell clusters with reduced TUNEL labelling and reduced
cleaved Caspase-3. No study to our knowledge has been done to up-regulate menin
within pancreatic development, although numerous studies of menin within adult tissues
have been performed to elucidate its function within adult tissues. As it has been
discussed in section 4.4, our results indicate that menin is required during fetal endocrine
development and its function differs from its anti-tumourigenic properties within the
mature adult pancreas. Overall, these results confirm the requirement of menin during
human fetal pancreatic development whereby menin functions to promote endocrine
progenitor proliferation, differentiation and cell survival.

4.6

Conclusion and Future Direction

In summary, this study uses two complementary methods of MEN1 knockdown and
MEN1 overexpression to provide evidence suggesting that menin is required for normal
endocrine differentiation within the human fetal pancreas. Our results indicate that
menin positively regulates pancreatic proliferation, cell survival, and normal islet
differentiation. Menin is therefore important within the islet progenitor pool, and also
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elicits its function in differentiation post-NGN3 expression, but before NKX2.2 and
NKX6.1 expression. Some potential future studies have been addressed earlier within the
discussion and alternative future studies may include determining which cell population
is apoptotic, examining where exactly menin exerts its role in differentiation within the
transcription factor cascade, and looking at which interacting partners or pathways menin
performs its functions in proliferation, cell survival, and differentiation.
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A.

B.

C.

Supplementary Figure 1.

Anti-Menin Antibody Control with Immunofluorescence

Techniques.
Human fetal pancreata sections from 15 wks of development were used to test the Rabbit
menin anti-human antibody by Bethyl Laboratories (Montgomery, TX, USA) for nonspecific binding. (A) Normal immunofluorescence staining (+ve control) where sections
were immunolabelled with anti-menin (primary) antibodies then visualized with Cy2
(green) conjugated secondary antibodies.

Nuclei were labelled with DAPI (blue).

Images display immunostaining for menin (green), DAPI (blue), and an overlay of the
images. Omission of the (B) primary (1 omit) or (C) the corresponding secondary
antibody (2 omit). Blood cells (containing no nucleus, indicated by DAPI staining)
showed high non-specific binding with the menin antibody however blood cells bind all
antibodies and can be distinguished by the lack of DAPI co-staining.
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Supplementary Figure 2.

Anti-Menin Antibody Control Using Western Blotting

Techniques.
Whole protein extracts from human fetal pancreata at 18, 21, and 22 wks were used to
test the western blotting specificity of the rabbit anti-human menin antibody from Bethyl
Laboratories (Montgomery, TX, USA). The molecular weight of menin is predicted to be
around 68 kDa. Normal menin antibody staining revealed multiple bands of non-specific
binding. The second brightest band at 40kDa was predominantly shown to be due to the
secondary antibody used (shown by 1° omit). The primary antibody had no background
noise when the 2° was omitted. Thus the true menin band is observed around 75kDa.
The protein extracts at each time point were taken from the same pancreatic aliquot and
run on the same gel in triplicate. The membrane was then cut to allow for consistent
membrane production conditions but different staining treatments.
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RNA Collection - siRNA

A.

Treatment
24hr
Ctrl
MsiRNA
48hr
Ctrl
MsiRNA
72hr
Ctrl
MsiRNA

Concentration
0.169
0.192
0.436
0.304
0.262
0.192

Purity Ratio
1.316
1.622
1.467
1.527
1.548
1.683

Sample: 15W 11H46 Wed June 1, 2011

B.

Supplementary Figure 3.

RNA Collection and Quality Control.

Extracted RNA was tested to determine the concentration, purity, and quality of each
sample and treatment group. A sample is shown where total RNA was extracted from
Islet-epithelial cell clusters which had been transfected with either control siRNA (Ctrl)
or MEN1 siRNA (MsiRNA/M) for a treatment period of 24, 48, or 72 hrs. (A) 1μL of
each treatment group was diluted and run through a spectrophotometer to determine the
O.D260 (total RNA concentration) and corrected OD ratio of A260/A280 (RNA purity).
(B) 1 μL of each treatment group was run on a 1% agarose gel stained with ethidium
bromide to test RNA Quality, two sharp and clear 28S and 18S rRNA bands were shown.
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Supplementary Figure 4.

Melting Curves and Derivative Melting Curves of qRT-

PCR Products.
For each qRT-PCR reaction the melting curve and derivative melting curve was
determined to ensure the quality of target sequence amplification. Shown is an example
of a reaction amplifying NGN3 mRNA where the melting curves (a) and derivative
melting curves (b) show that qRT-PCR assays have amplified the target sequences with
excellent specificity.
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A.

B.

Supplementary Figure 5.

Effect of MEN1 Knockdown and MEN1 Overexpression

on p18, p21, p27, and CyclinD1 Expression.
Islet-epithelial cell clusters were isolated from human fetal pancreata 15 to 19 wks. (A)
Clusters were transfected with either control siRNA (Ctrl-siRNA) or MEN1 siRNA
(MEN1-siRNA) for a 48 hr treatment period. qRT-PCR analysis of total p18, p21, p27,
and CyclinD1 mRNA for control and MEN1 siRNA treatments.

(B) Clusters were

transfected with either a control (Ctrl-EGFP) or a MEN1 (N2-M1) vector and cultured for
48 hrs. qRT-PCR analysis of total p18, p21, and p27 mRNA for control and N2-M1
treatment groups. Data were normalized to 18S rRNA and are expressed as means ±
SEM where n=4-6 per experimental group.
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A.

B.

Supplementary Figure 6.

Effect of MEN1 siRNA on the AKT and Wnt/β-catenin

Pathways.
Islet-epithelial cell clusters, isolated from human fetal pancreata 15 to 19 wks, were
transfected with either control siRNA or MEN1 siRNA for a 48 hr treatment. (A)
Western blot analysis of total phosphorylated AKT (pAKT) expression (60 kDa)
normalized to total AKT expression (60 kDa) for both treatment groups, n=3 per
treatment group. (B) Western blot analysis of total phosphorylated β-catenin (pβ-catenin)
expression (92 kDa) normalized to total β-Actin expression (42 kDa) for both treatment
groups, n=3 per treatment group. Data were expressed as means ± SEM.
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Supplementary Table 1: List of Antibodies/Antisera Used for Immunofluorescence
and Western-Blot Analyses.
Primary antibody

Dilution

Company, Location

mouse monoclonal β –Actin

1:5000a

Sigma, St. Louis, MO, USA

rabbit polyclonal AKT

1:3000a

Cell signaling, Danvers, MA, USA

mouse monoclonal

1:2000a

Cell signaling, Danvers, MA, USA

1:1000a

Cell signaling, Danvers, MA, USA

Phosphorylated AKT (Ser 473)
rabbit polyclonal Phosphorylated
β-Catenin (Ser 675)
a

dilution factor applied for western blot analysis. DSHB, Developmental Studies

Hybridoma Bank; JRL, Jackson Immunoresearch Laboratories
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